Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
<,31325302,EC50,"TSC3 showed potent in vitro activity against atovaquone-, dihydroartemisinin-, chloroquine- and mefloquine-resistant P. falciparum lines (EC50 <15 nM).",Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),nM,15,2172,DB00358,Mefloquine
>,31325302,selectivity index,The selectivity index (EC50 cells/EC50Pf W2 line) of TSC3 was >500 in two of three mammalian cell lines.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),,500,2173,DB00358,Mefloquine
,31325302,maximum blood concentration,A single oral dose of TSC3 at 16 mg/kg in healthy mice achieved a mean maximum blood concentration of 1883 ng/mL at 1 h after dosing and an elimination half-life of 48.7 h in groups of five mice.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),[ng] / [ml],1883,2174,DB00358,Mefloquine
,31325302,elimination half-life,A single oral dose of TSC3 at 16 mg/kg in healthy mice achieved a mean maximum blood concentration of 1883 ng/mL at 1 h after dosing and an elimination half-life of 48.7 h in groups of five mice.,Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325302/),h,48.7,2175,DB00358,Mefloquine
,15906639,Cmax,"For the dihydroartemisinin, the median (95% Cl) Cmax of 748 (304-1,470) ng/ml was observed at 1.5 (0.3-3.0) hours (tmax) after drug administration.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),[ng] / [ml],748,4050,DB00358,Mefloquine
,15906639,tmax,"For the dihydroartemisinin, the median (95% Cl) Cmax of 748 (304-1,470) ng/ml was observed at 1.5 (0.3-3.0) hours (tmax) after drug administration.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),h,1.5,4051,DB00358,Mefloquine
,15906639,AUC0-infinity,"The median (95% CI) values for AUC0-infinity, lambda(z) and tl/2z were 1.673 (1.08-2.88) microg.h/ml, 0.54(0.24-1.1)/hour and 1.3 (0.6-2.9) hours, respectively.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),[h·μg] / [ml],1.673,4052,DB00358,Mefloquine
,15906639,lambda(z),"The median (95% CI) values for AUC0-infinity, lambda(z) and tl/2z were 1.673 (1.08-2.88) microg.h/ml, 0.54(0.24-1.1)/hour and 1.3 (0.6-2.9) hours, respectively.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),1/[h],0.54,4053,DB00358,Mefloquine
,15906639,tl/2z,"The median (95% CI) values for AUC0-infinity, lambda(z) and tl/2z were 1.673 (1.08-2.88) microg.h/ml, 0.54(0.24-1.1)/hour and 1.3 (0.6-2.9) hours, respectively.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),h,1.3,4054,DB00358,Mefloquine
,15906639,Cmax,"For mefloquine, a median (95% Cl) Cmax of 1,000 (591-1,500) ng/ml was observed at 4 (2-6) hours (tmax) after drug administration.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),[ng] / [ml],"1,000",4055,DB00358,Mefloquine
,15906639,tmax,"For mefloquine, a median (95% Cl) Cmax of 1,000 (591-1,500) ng/ml was observed at 4 (2-6) hours (tmax) after drug administration.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),h,4,4056,DB00358,Mefloquine
,15906639,tmax,"For mefloquine, a median (95% Cl) Cmax of 1,000 (591-1,500) ng/ml was observed at 4 (2-6) hours (tmax) after drug administration.","Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),h,2-6,4057,DB00358,Mefloquine
,15906639,AUC0-168h,The median (95% CI) value for AUC0-168h was 3.92 (2.88-7.02) microg.h/ml.,"Investigation of bioavailability, pharmacokinetics and safety of new pediatric formulations of artesunate and mefloquine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906639/),[h·μg] / [ml],3.92,4058,DB00358,Mefloquine
,2785812,Time to peak concentrations,"Time to peak concentrations (mean +/- s.d. for mefloquine (5.70 +/- 0.95 h), sulphadoxine (3.75 +/- 2.03 h) and pyrimethamine (3.30 +/- 1.98 h) were similar to those observed by others after administration of the single compounds.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,5.70,5181,DB00358,Mefloquine
,2785812,Time to peak concentrations,"Time to peak concentrations (mean +/- s.d. for mefloquine (5.70 +/- 0.95 h), sulphadoxine (3.75 +/- 2.03 h) and pyrimethamine (3.30 +/- 1.98 h) were similar to those observed by others after administration of the single compounds.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,3.75,5182,DB00358,Mefloquine
,2785812,Time to peak concentrations,"Time to peak concentrations (mean +/- s.d. for mefloquine (5.70 +/- 0.95 h), sulphadoxine (3.75 +/- 2.03 h) and pyrimethamine (3.30 +/- 1.98 h) were similar to those observed by others after administration of the single compounds.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,3.30,5183,DB00358,Mefloquine
,2785812,t1/2s,"The t1/2s for mefloquine, sulphadoxine and pyrimethamine were 387 +/- 98 h, 255 +/- 61 h and 114 +/- 42 h, respectively.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,387,5184,DB00358,Mefloquine
,2785812,t1/2s,"The t1/2s for mefloquine, sulphadoxine and pyrimethamine were 387 +/- 98 h, 255 +/- 61 h and 114 +/- 42 h, respectively.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,255,5185,DB00358,Mefloquine
,2785812,t1/2s,"The t1/2s for mefloquine, sulphadoxine and pyrimethamine were 387 +/- 98 h, 255 +/- 61 h and 114 +/- 42 h, respectively.",Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2785812/),h,114,5186,DB00358,Mefloquine
,8957153,elimination half-life,"Absorption is incomplete and elimination is fast, with and elimination half-life of 2 to 5 hours.",Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8957153/),h,2 to 5,5254,DB00358,Mefloquine
less,8957153,elimination half-life,"The reported elimination half-life of artesunate is less than 1 hour, and for artemether the figure is 3 to 11 hours.",Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8957153/),h,1,5255,DB00358,Mefloquine
,8957153,elimination half-life,"The reported elimination half-life of artesunate is less than 1 hour, and for artemether the figure is 3 to 11 hours.",Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8957153/),h,3 to 11,5256,DB00358,Mefloquine
over,8957153,elimination half-life,"Arteether, dissolved in oil for intramuscular administration, has a much longer elimination half-life of over 20 hours.",Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8957153/),h,20,5257,DB00358,Mefloquine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],0.07,6943,DB00358,Mefloquine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],0.17,6944,DB00358,Mefloquine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],0.81,6945,DB00358,Mefloquine
,25092696,Clearance,Clearance was significantly lower in malaria infection than in healthy (adult) humans for quinine (0.07 versus 0.17 liter/h/kg; P = 0.0002) and dihydroartemisinin (0.81 versus 1.11 liters/h/kg; P = 0.04; power = 0.6).,Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092696/),[l] / [h·kg],1.11,6946,DB00358,Mefloquine
,8866337,volume of distribution (Vd),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),ml,7.53,8764,DB00358,Mefloquine
,8866337,clearance (CL),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),[ml] / [min],0.11,8765,DB00358,Mefloquine
,8866337,initial distribution half-life (initial t1/2),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),min,14.62,8766,DB00358,Mefloquine
,8866337,terminal half-life (terminal t1/2),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),min,138.7,8767,DB00358,Mefloquine
,8866337,AUC,"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),[mg] / [min·ml],606,8768,DB00358,Mefloquine
,8866337,elimination rate constant (Ke),"Halofantrine parameter estimates (mean +/- s.d.) were: volume of distribution (Vd), 7.53 +/- 1.45 mL (g liver)-1; clearance (CL), 0.11 +/- 0.07 mL min-1 (g liver)-1; initial distribution half-life (initial t1/2), 14.62 +/- 2.38 min; terminal half-life (terminal t1/2), 138.7 +/- 178.8 min; AUC 606 +/- 194 mg mL-1 min-1 (g liver)-1; elimination rate constant (Ke), 0.0135 +/- 0.012 min-1.",Mefloquine effect on disposition of halofantrine in the isolated perfused rat liver. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866337/),1/[min],0.0135,8769,DB00358,Mefloquine
,8169835,apparent first-order distribution (lambda 1),"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.043,14426,DB00358,Mefloquine
,8169835,elimination (lambda z),"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.043,14427,DB00358,Mefloquine
,8169835,rate constants,"The apparent first-order distribution (lambda 1) and elimination (lambda z) rate constants were 0.043 +/- 0.014 min-1 and 0.020 +/- 0.007 min-1, respectively.",Mefloquine transfer during in vitro human placenta perfusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),1/[min],0.020,14428,DB00358,Mefloquine
,8169835,mass ratio,The fetomaternal mass ratio became constant (0.46 +/- 0.07) after 120 min of perfusion and the time needed to achieve equal concentrations on both sides of the placenta was 178 +/- 31 min.,Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),,0.46,14429,DB00358,Mefloquine
,8169835,time needed to achieve,The fetomaternal mass ratio became constant (0.46 +/- 0.07) after 120 min of perfusion and the time needed to achieve equal concentrations on both sides of the placenta was 178 +/- 31 min.,Mefloquine transfer during in vitro human placenta perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),min,178,14430,DB00358,Mefloquine
,8169835,clearance,MQ clearance was 3.36 +/- 0.38 ml/min.,Mefloquine transfer during in vitro human placenta perfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169835/),[ml] / [min],3.36,14431,DB00358,Mefloquine
,9860148,maximum plasma concentration (Cmax,"The pharmacokinetics of mefloquine after administration of M1 and M2 tablets were significantly different as reflected by the respective mean values of maximum plasma concentration (Cmax 656 vs 1018 ng x ml(-1)), time to reach maximum concentration (tmax 46 vs 13 h) and area under the plasma concentration-time curve (AUC0-->infinity 338 vs 432 microg x h x ml(-1)).",Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),[ng] / [ml],656,19790,DB00358,Mefloquine
,9860148,maximum plasma concentration (Cmax,"The pharmacokinetics of mefloquine after administration of M1 and M2 tablets were significantly different as reflected by the respective mean values of maximum plasma concentration (Cmax 656 vs 1018 ng x ml(-1)), time to reach maximum concentration (tmax 46 vs 13 h) and area under the plasma concentration-time curve (AUC0-->infinity 338 vs 432 microg x h x ml(-1)).",Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),[ng] / [ml],1018,19791,DB00358,Mefloquine
,9860148,time to reach maximum concentration (tmax,"The pharmacokinetics of mefloquine after administration of M1 and M2 tablets were significantly different as reflected by the respective mean values of maximum plasma concentration (Cmax 656 vs 1018 ng x ml(-1)), time to reach maximum concentration (tmax 46 vs 13 h) and area under the plasma concentration-time curve (AUC0-->infinity 338 vs 432 microg x h x ml(-1)).",Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),h,46,19792,DB00358,Mefloquine
,9860148,time to reach maximum concentration (tmax,"The pharmacokinetics of mefloquine after administration of M1 and M2 tablets were significantly different as reflected by the respective mean values of maximum plasma concentration (Cmax 656 vs 1018 ng x ml(-1)), time to reach maximum concentration (tmax 46 vs 13 h) and area under the plasma concentration-time curve (AUC0-->infinity 338 vs 432 microg x h x ml(-1)).",Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),h,13,19793,DB00358,Mefloquine
,9860148,area under the plasma concentration-time curve (AUC0-->infinity,"The pharmacokinetics of mefloquine after administration of M1 and M2 tablets were significantly different as reflected by the respective mean values of maximum plasma concentration (Cmax 656 vs 1018 ng x ml(-1)), time to reach maximum concentration (tmax 46 vs 13 h) and area under the plasma concentration-time curve (AUC0-->infinity 338 vs 432 microg x h x ml(-1)).",Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),[h·μg] / [ml],338,19794,DB00358,Mefloquine
,9860148,area under the plasma concentration-time curve (AUC0-->infinity,"The pharmacokinetics of mefloquine after administration of M1 and M2 tablets were significantly different as reflected by the respective mean values of maximum plasma concentration (Cmax 656 vs 1018 ng x ml(-1)), time to reach maximum concentration (tmax 46 vs 13 h) and area under the plasma concentration-time curve (AUC0-->infinity 338 vs 432 microg x h x ml(-1)).",Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),[h·μg] / [ml],432,19795,DB00358,Mefloquine
,9860148,elimination half-lives,No significant differences existed between the elimination half-lives of the two formulations (394 vs 396 h).,Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),h,394,19796,DB00358,Mefloquine
,9860148,elimination half-lives,No significant differences existed between the elimination half-lives of the two formulations (394 vs 396 h).,Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),h,396,19797,DB00358,Mefloquine
,9860148,relative bioavailability,The relative bioavailability (M1 vs M2) was 0.78 and ranged from 0.38 to 1.37.,Lack of bioequivalence of a generic mefloquine tablet with the standard product. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9860148/),,0.78,19798,DB00358,Mefloquine
,7957448,clearance time,No statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given MSP plus primaquine (7 +/- 2.7 days) than the children given MSP alone (21.9 +/- 4.4 days) (P < 0.01).,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,7,23703,DB00358,Mefloquine
,7957448,clearance time,No statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given MSP plus primaquine (7 +/- 2.7 days) than the children given MSP alone (21.9 +/- 4.4 days) (P < 0.01).,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,21.9,23704,DB00358,Mefloquine
,7957448,Cmax,Mean Cmax was 7.4 +/- 5.2 h in group I and 6.6 +/- 7.0 h in group II.,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),h,7.4,23705,DB00358,Mefloquine
,7957448,Cmax,Mean Cmax was 7.4 +/- 5.2 h in group I and 6.6 +/- 7.0 h in group II.,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),h,6.6,23706,DB00358,Mefloquine
,7957448,t1/2,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,9.8,23707,DB00358,Mefloquine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[ml] / [kg·min],0.43,23708,DB00358,Mefloquine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,9.3,23709,DB00358,Mefloquine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[ml] / [kg·min],0.41,23710,DB00358,Mefloquine
,7957448,Vd/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[l] / [kg],8.84,23711,DB00358,Mefloquine
,7957448,Vd/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[l] / [kg],8.91,23712,DB00358,Mefloquine
,23175556,parasitemia half-life (half-life),Overall median (interquartile range [IQR]) parasitemia half-life (half-life) was 6.03 (4.89-7.28) hours in Pailin versus 3.42 (2.20-4.85) hours in Wang Pha (P = .0001).,Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175556/),h,6.03,24027,DB00358,Mefloquine
,23175556,parasitemia half-life (half-life),Overall median (interquartile range [IQR]) parasitemia half-life (half-life) was 6.03 (4.89-7.28) hours in Pailin versus 3.42 (2.20-4.85) hours in Wang Pha (P = .0001).,Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175556/),h,3.42,24028,DB00358,Mefloquine
,8131255,fever clearance time (FCT),"The patients who received mefloquine alone all showed initially good responses to the treatment, with mean +/- SD values for the fever clearance time (FCT) and parasite clearance time (PCT) of 44.7 +/- 43.1 hours and 82.3 +/- 52.3 hours, respectively.",Pharmacokinetics of mefloquine alone or in combination with artesunate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),h,44.7,24580,DB00358,Mefloquine
,8131255,parasite clearance time (PCT),"The patients who received mefloquine alone all showed initially good responses to the treatment, with mean +/- SD values for the fever clearance time (FCT) and parasite clearance time (PCT) of 44.7 +/- 43.1 hours and 82.3 +/- 52.3 hours, respectively.",Pharmacokinetics of mefloquine alone or in combination with artesunate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),h,82.3,24581,DB00358,Mefloquine
,8131255,FCT,"The patients who received the combination treatment were clinically markedly improved, with a relatively shorter FCT (31.2 +/- 12.4 hours) and significantly shorter PCT (47.5 +/- 19.6 hours).",Pharmacokinetics of mefloquine alone or in combination with artesunate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),h,31.2,24582,DB00358,Mefloquine
,8131255,PCT,"The patients who received the combination treatment were clinically markedly improved, with a relatively shorter FCT (31.2 +/- 12.4 hours) and significantly shorter PCT (47.5 +/- 19.6 hours).",Pharmacokinetics of mefloquine alone or in combination with artesunate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),h,47.5,24583,DB00358,Mefloquine
,8131255,maximum concentration (Cmax,Artesunate caused three significant changes in mefloquine pharmacokinetics: a decrease in the maximum concentration (Cmax: 1623 ng.ml-1 versus 2212 ng.ml-1); an increase in the clearance rate (Cl/f:2.9 ml.min-1.kg-1 versus 1.1 ml.min-1.kg-1); and an expansion of the volume of distribution (Vdz/f: 31.8 l.kg-1 versus 25.0 l.kg-1).,Pharmacokinetics of mefloquine alone or in combination with artesunate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),[ng] / [ml],1623,24584,DB00358,Mefloquine
,8131255,maximum concentration (Cmax,Artesunate caused three significant changes in mefloquine pharmacokinetics: a decrease in the maximum concentration (Cmax: 1623 ng.ml-1 versus 2212 ng.ml-1); an increase in the clearance rate (Cl/f:2.9 ml.min-1.kg-1 versus 1.1 ml.min-1.kg-1); and an expansion of the volume of distribution (Vdz/f: 31.8 l.kg-1 versus 25.0 l.kg-1).,Pharmacokinetics of mefloquine alone or in combination with artesunate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),[ng] / [ml],2212,24585,DB00358,Mefloquine
,8131255,clearance rate (Cl/f,Artesunate caused three significant changes in mefloquine pharmacokinetics: a decrease in the maximum concentration (Cmax: 1623 ng.ml-1 versus 2212 ng.ml-1); an increase in the clearance rate (Cl/f:2.9 ml.min-1.kg-1 versus 1.1 ml.min-1.kg-1); and an expansion of the volume of distribution (Vdz/f: 31.8 l.kg-1 versus 25.0 l.kg-1).,Pharmacokinetics of mefloquine alone or in combination with artesunate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),[ml] / [kg·min],2.9,24586,DB00358,Mefloquine
,8131255,clearance rate (Cl/f,Artesunate caused three significant changes in mefloquine pharmacokinetics: a decrease in the maximum concentration (Cmax: 1623 ng.ml-1 versus 2212 ng.ml-1); an increase in the clearance rate (Cl/f:2.9 ml.min-1.kg-1 versus 1.1 ml.min-1.kg-1); and an expansion of the volume of distribution (Vdz/f: 31.8 l.kg-1 versus 25.0 l.kg-1).,Pharmacokinetics of mefloquine alone or in combination with artesunate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),[ml] / [kg·min],1.1,24587,DB00358,Mefloquine
,8131255,volume of distribution (Vdz/f,Artesunate caused three significant changes in mefloquine pharmacokinetics: a decrease in the maximum concentration (Cmax: 1623 ng.ml-1 versus 2212 ng.ml-1); an increase in the clearance rate (Cl/f:2.9 ml.min-1.kg-1 versus 1.1 ml.min-1.kg-1); and an expansion of the volume of distribution (Vdz/f: 31.8 l.kg-1 versus 25.0 l.kg-1).,Pharmacokinetics of mefloquine alone or in combination with artesunate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),[l] / [kg],31.8,24588,DB00358,Mefloquine
,8131255,volume of distribution (Vdz/f,Artesunate caused three significant changes in mefloquine pharmacokinetics: a decrease in the maximum concentration (Cmax: 1623 ng.ml-1 versus 2212 ng.ml-1); an increase in the clearance rate (Cl/f:2.9 ml.min-1.kg-1 versus 1.1 ml.min-1.kg-1); and an expansion of the volume of distribution (Vdz/f: 31.8 l.kg-1 versus 25.0 l.kg-1).,Pharmacokinetics of mefloquine alone or in combination with artesunate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131255/),[l] / [kg],25.0,24589,DB00358,Mefloquine
,3878153,concentrations,"After oral administration of 750 mg mefloquine to six volunteers, absorption, was apparently slow, with plasma mefloquine concentrations at 24 h (559 +/- 181 ng ml-1; mean +/- s.d.) higher than at 6 h (459 +/- 166 ng ml-1).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[ng] / [ml],559,26083,DB00358,Mefloquine
,3878153,concentrations,"After oral administration of 750 mg mefloquine to six volunteers, absorption, was apparently slow, with plasma mefloquine concentrations at 24 h (559 +/- 181 ng ml-1; mean +/- s.d.) higher than at 6 h (459 +/- 166 ng ml-1).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[ng] / [ml],459,26084,DB00358,Mefloquine
,3878153,elimination half-life,"The elimination half-life was 373 +/- 249 h, oral clearance was 5.09 +/- 2.7 1 h-1, and apparent volume of distribution was 35.7 +/- 30.7 l kg-1 (assuming 100% bioavailability).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),h,373,26085,DB00358,Mefloquine
,3878153,oral clearance,"The elimination half-life was 373 +/- 249 h, oral clearance was 5.09 +/- 2.7 1 h-1, and apparent volume of distribution was 35.7 +/- 30.7 l kg-1 (assuming 100% bioavailability).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[1] / [h],5.09,26086,DB00358,Mefloquine
,3878153,apparent volume of distribution,"The elimination half-life was 373 +/- 249 h, oral clearance was 5.09 +/- 2.7 1 h-1, and apparent volume of distribution was 35.7 +/- 30.7 l kg-1 (assuming 100% bioavailability).",The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3878153/),[l] / [kg],35.7,26087,DB00358,Mefloquine
,1820638,time taken to clear the parasites (PCT),"The time taken to clear the parasites (PCT) was significantly longer in patients with recrudescence (99.6 +/- 36.9 and 63.0 +/- 8.9 hours); however, there was no difference regarding fever clearance time (FCT: 39.0 +/- 16.1 and 31.0 +/- 21.3 hours).",Pharmacokinetics of mefloquine in treatment failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820638/),h,99.6,35431,DB00358,Mefloquine
,1820638,time taken to clear the parasites (PCT),"The time taken to clear the parasites (PCT) was significantly longer in patients with recrudescence (99.6 +/- 36.9 and 63.0 +/- 8.9 hours); however, there was no difference regarding fever clearance time (FCT: 39.0 +/- 16.1 and 31.0 +/- 21.3 hours).",Pharmacokinetics of mefloquine in treatment failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820638/),h,63.0,35432,DB00358,Mefloquine
,1820638,fever clearance time (FCT,"The time taken to clear the parasites (PCT) was significantly longer in patients with recrudescence (99.6 +/- 36.9 and 63.0 +/- 8.9 hours); however, there was no difference regarding fever clearance time (FCT: 39.0 +/- 16.1 and 31.0 +/- 21.3 hours).",Pharmacokinetics of mefloquine in treatment failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820638/),h,39.0,35433,DB00358,Mefloquine
,1820638,fever clearance time (FCT,"The time taken to clear the parasites (PCT) was significantly longer in patients with recrudescence (99.6 +/- 36.9 and 63.0 +/- 8.9 hours); however, there was no difference regarding fever clearance time (FCT: 39.0 +/- 16.1 and 31.0 +/- 21.3 hours).",Pharmacokinetics of mefloquine in treatment failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820638/),h,31.0,35434,DB00358,Mefloquine
,6980423,elimination half-life,"The elimination half-life of the unmetabolized WR 177,602 in plasma was estimated to be 16.1 h.",Disposition of the diastereoisomer of mefloquine in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6980423/),h,16.1,35454,DB00358,Mefloquine
,6980423,elimination half-lives,"The elimination half-lives of the unmetabolized drug in urine and feces were 8.0 and 6.9 h, respectively.",Disposition of the diastereoisomer of mefloquine in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6980423/),h,8.0,35455,DB00358,Mefloquine
,6980423,elimination half-lives,"The elimination half-lives of the unmetabolized drug in urine and feces were 8.0 and 6.9 h, respectively.",Disposition of the diastereoisomer of mefloquine in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6980423/),h,6.9,35456,DB00358,Mefloquine
,10432050,elimination half-life,"The Fab exhibited a two-compartment, dose-proportional kinetics with an average elimination half-life of 12.0 hr, with about 20% being excreted renally.",Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatment for severe malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10432050/),h,12.0,38675,DB00358,Mefloquine
,29933218,Cmin,"Assessment of mefloquine plasma concentrations by HPLC and modeling using a two-compartment pharmacokinetic model with first-order absorption showed that >90% of the expected steady-state levels (Cmin 1.15 mg/L, Cmax 2.63 mg/L) were reached.",Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933218/),[mg] / [l],1.15,39558,DB00358,Mefloquine
,29933218,Cmax,"Assessment of mefloquine plasma concentrations by HPLC and modeling using a two-compartment pharmacokinetic model with first-order absorption showed that >90% of the expected steady-state levels (Cmin 1.15 mg/L, Cmax 2.63 mg/L) were reached.",Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933218/),[mg] / [l],2.63,39559,DB00358,Mefloquine
,1888626,peak blood drug concentrations,Mean (s.d.) peak blood drug concentrations of 2031 (831) ng ml-1 were reached in a median of 8 (range 6-24) h.,Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888626/),[ng] / [ml],2031,43220,DB00358,Mefloquine
,1888626,oral clearance,"Mean (s.d.) estimates for oral clearance and mean residence time were 0.52 (0.27) ml min -1 kg -1 and 15.3 (4.7) days, respectively.",Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888626/),-1·-1·kg·min·ml,0.52,43221,DB00358,Mefloquine
,1888626,mean residence time,"Mean (s.d.) estimates for oral clearance and mean residence time were 0.52 (0.27) ml min -1 kg -1 and 15.3 (4.7) days, respectively.",Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888626/),d,15.3,43222,DB00358,Mefloquine
,9491824,peak concentration,"Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),μM,29.5,49096,DB00358,Mefloquine
,9491824,elimination t1/2,"Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),min,2.7,49097,DB00358,Mefloquine
,9491824,CL,"Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),[l] / [h·kg],2.33,49098,DB00358,Mefloquine
,9491824,V,"Following i.v. bolus, ARTS had a peak concentration of 29.5 microM (11 mg l[-1]), elimination t1/2 = 2.7 min, CL = 2.33 l h(-1) kg(-1) and V = 0.14 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),[l] / [kg],0.14,49099,DB00358,Mefloquine
,9491824,Cmax,"The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),μM,9.3,49100,DB00358,Mefloquine
,9491824,t1/2,"The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),min,40,49101,DB00358,Mefloquine
,9491824,CL,"The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),[l] / [h·kg],0.75,49102,DB00358,Mefloquine
,9491824,V,"The Cmax for DHA was 9.3 microM (2.64 mg l[-1]), t1/2 = 40 min, CL =0.75 l h(-1) kg(-1) and V = 0.76 l kg(-1).",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),[l] / [kg],0.76,49103,DB00358,Mefloquine
,9491824,relative bioavailability,"Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),%,82,49104,DB00358,Mefloquine
,9491824,Cmax,"Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),μM,2.6,49105,DB00358,Mefloquine
,9491824,Cmax,"Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),[mg] / [l],0.74,49106,DB00358,Mefloquine
,9491824,t1/2,"Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),min,39,49107,DB00358,Mefloquine
,9491824,MAT,"Following oral ARTS, relative bioavailability of DHA was 82%, Cmax was 2.6 microM (0.74 mg l[-1]), t1/2 = 39 min, and MAT = 67 min.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),min,67,49108,DB00358,Mefloquine
,9491824,PCT50,"Overall, the PCT50 and fever clearance time (FCT) were 6.5 h and 24 h, respectively.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),h,6.5,49109,DB00358,Mefloquine
,9491824,fever clearance time (FCT),"Overall, the PCT50 and fever clearance time (FCT) were 6.5 h and 24 h, respectively.",A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491824/),h,24,49110,DB00358,Mefloquine
,9217701,exposure time,The exposure time for artemisinin was 3 hours twice daily and for mefloquine 24 hours.,Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217701/),h,3,49175,DB00358,Mefloquine
,9217701,exposure time,The exposure time for artemisinin was 3 hours twice daily and for mefloquine 24 hours.,Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217701/),,24,49176,DB00358,Mefloquine
,8835620,Maximum concentrations,Maximum concentrations of 2302 (750) and 2399 (418) ng/ml were achieved at 15.9 (4.5) and 17.1 (3.1) h after a single and a divided-dose regimen respectively.,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[ng] / [ml],2302,50988,DB00358,Mefloquine
,8835620,Maximum concentrations,Maximum concentrations of 2302 (750) and 2399 (418) ng/ml were achieved at 15.9 (4.5) and 17.1 (3.1) h after a single and a divided-dose regimen respectively.,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[ng] / [ml],2399,50989,DB00358,Mefloquine
,8835620,AUC,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[d·μg] / [ml],21.78,50990,DB00358,Mefloquine
,8835620,AUC,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[d·μg] / [ml],20.7,50991,DB00358,Mefloquine
,8835620,Vdz/f,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[l] / [kg],23.7,50992,DB00358,Mefloquine
,8835620,Vdz/f,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[l] / [kg],24.9,50993,DB00358,Mefloquine
,8835620,CL/f,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[ml] / [kg·min],0.899,50994,DB00358,Mefloquine
,8835620,CL/f,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),[ml] / [kg·min],1.02,50995,DB00358,Mefloquine
,8835620,t1/2z,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),d,12.5,50996,DB00358,Mefloquine
,8835620,t1/2z,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),d,11.4,50997,DB00358,Mefloquine
,8835620,MRT,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),d,16.2,50998,DB00358,Mefloquine
,8835620,MRT,Other parameters were also comparable between the 2 regimens of mefloquine [AUC: 21.78 (5.99) vs 20.7 (604) micrograms.day/ml; Vdz/f: 23.7 (3.4) vs 24.9 (3.7) L/kg; CL/f: 0.899 (0.23) vs 1.02 (0.51) ml/min/kg; t1/2z: 12.5 (3.2) vs 11.4 (2.1) days; MRT: 16.2 (2.2) vs 16.8 (3.1) days].,Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835620/),d,16.8,50999,DB00358,Mefloquine
,2208897,half-life,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,1 to 4,53513,DB00358,Mefloquine
,2208897,time to peak concentration,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,7 to 24,53514,DB00358,Mefloquine
,2208897,time to peak concentration,These have shown in healthy volunteers that mefloquine is absorbed with a half-life of 1 to 4 hours and a time to peak concentration of 7 to 24 hours (median 16.7 hours).,Clinical pharmacokinetics of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),h,16.7,53515,DB00358,Mefloquine
,2208897,peak blood concentrations,Mean peak blood concentrations have ranged between 50 and 110 (median 83) ng/ml/mg/kg.,Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],50 and 110,53516,DB00358,Mefloquine
,2208897,peak blood concentrations,Mean peak blood concentrations have ranged between 50 and 110 (median 83) ng/ml/mg/kg.,Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],83,53517,DB00358,Mefloquine
,2208897,total apparent volume of distribution (Vd/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [kg],19.2,53518,DB00358,Mefloquine
,2208897,systemic clearance (CL/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [h·kg],0.022 to 0.073,53519,DB00358,Mefloquine
,2208897,systemic clearance (CL/f),"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[l] / [h·kg],0.026,53520,DB00358,Mefloquine
,2208897,terminal elimination half-life,"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),d,13.8 to 40.9,53521,DB00358,Mefloquine
,2208897,terminal elimination half-life,"Estimates of total apparent volume of distribution (Vd/f) have ranged from 13.3 to 40.9 (median 19.2) L/kg, systemic clearance (CL/f) from 0.022 to 0.073 L/h/kg (median 0.026 L/h/kg), and terminal elimination half-life from 13.8 to 40.9 days (median 20 days).",Clinical pharmacokinetics of mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),d,20,53522,DB00358,Mefloquine
,2208897,peak blood concentrations,"In uncomplicated falciparum malaria, peak blood concentrations are 2 to 3 times higher than those in healthy subjects ranging from 112 to 209 (median 144) ng/ml/mg/kg because of contraction in the total apparent volume of distribution.",Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],112 to 209,53523,DB00358,Mefloquine
,2208897,peak blood concentrations,"In uncomplicated falciparum malaria, peak blood concentrations are 2 to 3 times higher than those in healthy subjects ranging from 112 to 209 (median 144) ng/ml/mg/kg because of contraction in the total apparent volume of distribution.",Clinical pharmacokinetics of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),[ng] / [kg·mg·ml],144,53524,DB00358,Mefloquine
exceeds,2208897,plasma protein binding,Mefloquine absorption appears to be reduced in severe falciparum malaria; plasma protein binding exceeds 98% in both healthy subjects and patients.,Clinical pharmacokinetics of mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2208897/),%,98,53525,DB00358,Mefloquine
,21801400,total MCD,The total MCD of tafenoquine required in combination regimens for radical cure was ten-fold lower (1.8 mg/kg versus 18 mg/kg) than for monotherapy.,Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),,1,55856,DB00358,Mefloquine
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],20-84,55857,DB00358,Mefloquine
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],"550-1,100",55858,DB00358,Mefloquine
,11850261,Emax,"The Emax was estimated as 28.6 oral h, and the 50% effective concentration was 1.6 mg/kg of body weight.",Oral artesunate dose-response relationship in acute falciparum malaria. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850261/),h·oral,28.6,60078,DB00358,Mefloquine
,11850261,50% effective concentration,"The Emax was estimated as 28.6 oral h, and the 50% effective concentration was 1.6 mg/kg of body weight.",Oral artesunate dose-response relationship in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850261/),[mg] / [kg],1.6,60079,DB00358,Mefloquine
,20929590,PCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,32.0,60948,DB00358,Mefloquine
,20929590,PCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,24.0,60949,DB00358,Mefloquine
,20929590,FCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,30.0,60950,DB00358,Mefloquine
,20929590,FCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,26.0,60951,DB00358,Mefloquine
,2225700,Efficacy,Efficacy was 82% for 1500 mg and 63% for 750 mg.,Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225700/),%,82,61226,DB00358,Mefloquine
,2225700,Efficacy,Efficacy was 82% for 1500 mg and 63% for 750 mg.,Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225700/),%,63,61227,DB00358,Mefloquine
,1884748,maximum whole blood mefloquine concentration,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[ng] / [ml],1648,62449,DB00358,Mefloquine
,1884748,maximum whole blood mefloquine concentration,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[ng] / [ml],1228,62450,DB00358,Mefloquine
,1884748,terminal half life,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),d,15.3,62451,DB00358,Mefloquine
,1884748,terminal half life,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),d,17.7,62452,DB00358,Mefloquine
,1884748,mean residence time,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),d,20.1,62453,DB00358,Mefloquine
,1884748,mean residence time,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),d,23.4,62454,DB00358,Mefloquine
,1884748,volume of distribution at steady state,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[l] / [kg],14.1,62455,DB00358,Mefloquine
,1884748,volume of distribution at steady state,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with ampicillin (1648 vs 1228 ng.ml-1), as well as a significantly reduced terminal half life (15.3 vs 17.7 days), mean residence time (20.1 vs 23.4 days) and volume of distribution at steady state (14.1 vs 19.4 l.kg-1).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[l] / [kg],19.4,62456,DB00358,Mefloquine
,1884748,AUC from zero time to infinity,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 5 days was significantly increased by ampicillin (4.86 vs 3.27 micrograms.ml-1 day).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[d·μg] / [ml],4.86,62457,DB00358,Mefloquine
,1884748,AUC from zero time to 5 days,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 5 days was significantly increased by ampicillin (4.86 vs 3.27 micrograms.ml-1 day).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[d·μg] / [ml],4.86,62458,DB00358,Mefloquine
,1884748,AUC from zero time to 5 days,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 5 days was significantly increased by ampicillin (4.86 vs 3.27 micrograms.ml-1 day).",Effect of ampicillin on mefloquine pharmacokinetics in Thai males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884748/),[d·μg] / [ml],3.27,62459,DB00358,Mefloquine
,8249080,elimination half-life,"Mefloquine is an antimalarial drug with a 3-week elimination half-life, which has led to concerns that toxic accumulation may occur during weekly administration for long-term malaria chemoprophylaxis.",Steady state pharmacokinetics of mefloquine in long-term travellers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249080/),week,3,64688,DB00358,Mefloquine
,9180598,volume of distribution/bioavailability,"The following pharmacokinetic results were found (all mean +/- SD); calculated volume of distribution/bioavailability = 22.8 +/- 16.6 L.kg-1, mean absorption time = 1.16 +/- 0.92 hr, calculated maximum concentration = 364 +/- 250 micrograms.",The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180598/),[l] / [kg],22.8,69642,DB00358,Mefloquine
,9180598,mean absorption time,"The following pharmacokinetic results were found (all mean +/- SD); calculated volume of distribution/bioavailability = 22.8 +/- 16.6 L.kg-1, mean absorption time = 1.16 +/- 0.92 hr, calculated maximum concentration = 364 +/- 250 micrograms.",The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180598/),h,1.16,69643,DB00358,Mefloquine
,9180598,maximum concentration,"The following pharmacokinetic results were found (all mean +/- SD); calculated volume of distribution/bioavailability = 22.8 +/- 16.6 L.kg-1, mean absorption time = 1.16 +/- 0.92 hr, calculated maximum concentration = 364 +/- 250 micrograms.",The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180598/),μg,364,69644,DB00358,Mefloquine
,9180598,elimination half-life,"L-1 occurring at 2.88 +/- 1.71 hr after drug intake, and an elimination half-life of 2.72 +/- 1.76 hr.",The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180598/),h,2.72,69645,DB00358,Mefloquine
,9180598,parasite clearance time,"Parasites disappeared rapidly, with a mean parasite clearance time of 36 hr.",The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180598/),h,36,69646,DB00358,Mefloquine
,21751074,Maximum bound,"Maximum bound and unbound brain levels of WR319691 were 97 and 0.05 ng/g versus approximately 1,600 and 3.2 ng/g for mefloquine.","Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),[ng] / [g],97,72525,DB00358,Mefloquine
,21751074,Maximum bound,"Maximum bound and unbound brain levels of WR319691 were 97 and 0.05 ng/g versus approximately 1,600 and 3.2 ng/g for mefloquine.","Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),[ng] / [g],0.05,72526,DB00358,Mefloquine
,21751074,Maximum bound,"Maximum bound and unbound brain levels of WR319691 were 97 and 0.05 ng/g versus approximately 1,600 and 3.2 ng/g for mefloquine.","Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),[ng] / [g],"1,600",72527,DB00358,Mefloquine
,21751074,unbound brain levels,"Maximum bound and unbound brain levels of WR319691 were 97 and 0.05 ng/g versus approximately 1,600 and 3.2 ng/g for mefloquine.","Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),[ng] / [g],0.05,72528,DB00358,Mefloquine
,21751074,unbound brain levels,"Maximum bound and unbound brain levels of WR319691 were 97 and 0.05 ng/g versus approximately 1,600 and 3.2 ng/g for mefloquine.","Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),[ng] / [g],3.2,72529,DB00358,Mefloquine
,21751074,half-life,The half-life of WR319691 in plasma was approximately 13 h versus 23 h for mefloquine.,"Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),h,13,72530,DB00358,Mefloquine
,21751074,half-life,The half-life of WR319691 in plasma was approximately 13 h versus 23 h for mefloquine.,"Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21751074/),h,23,72531,DB00358,Mefloquine
,8808179,total AUC[Cmax,"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[ng] / [ml],"1,290",79971,DB00358,Mefloquine
,8808179,total AUC[Cmax,"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[ng] / [ml],"1,820",79972,DB00358,Mefloquine
,8808179,AUC[0-24 h],"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[d·μg] / [ml],0.99,79973,DB00358,Mefloquine
,8808179,AUC[0-24 h],"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[d·μg] / [ml],1.33,79974,DB00358,Mefloquine
,8808179,AUC[0-48 h],"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[d·μg] / [ml],1.78,79975,DB00358,Mefloquine
,8808179,AUC[0-48 h],"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[d·μg] / [ml],2.67,79976,DB00358,Mefloquine
,8808179,AUC[0-72 h],"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[d·μg] / [ml],2.74,79977,DB00358,Mefloquine
,8808179,AUC[0-72 h],"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),[d·μg] / [ml],4.54,79978,DB00358,Mefloquine
,8808179,AUC,"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),d·ml·μg,11.11,79979,DB00358,Mefloquine
,8808179,AUC,"This was evident by the significantly lower values of Cmax, AUC[0-24 h], AUC[0-48 h], AUC[0-72 h], as well as total AUC[Cmax: 1,290 (827-2,619) vs 1,820 (1,283-2,531) ng.ml-1; AUC[0-24 h]: 0.99 (0.64-1.41) vs 1.33 (1.07-1.95) micrograms.day.ml-1; AUC[0-48 h]: 1.78(1.23-2.58) vs 2.67 (2.09-3.84) micrograms.day.ml-1; AUC[0-72 h]: 2.74 (1.63-3.6) vs 4.54 (2.88-5.38) micrograms.day.ml-1; AUC: 11.11 (6-20.96) vs 15.29 (9.3-36.71) micrograms.day.ml-1].","Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),d·ml·μg,15.29,79980,DB00358,Mefloquine
,8808179,Tmax,Tmax was also delayed with the combination regimen [14 (5-24) vs 6 (4-16) h].,"Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),h,14,79981,DB00358,Mefloquine
,8808179,Tmax,Tmax was also delayed with the combination regimen [14 (5-24) vs 6 (4-16) h].,"Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),h,6,79982,DB00358,Mefloquine
,8808179,t1/2z,Terminal elimination half-lives were comparable [t1/2z: 11.1 (6.8-14.3) vs 13.4 (10.5-19.1) h].,"Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),h,11.1,79983,DB00358,Mefloquine
,8808179,t1/2z,Terminal elimination half-lives were comparable [t1/2z: 11.1 (6.8-14.3) vs 13.4 (10.5-19.1) h].,"Pharmacokinetics of mefloquine, when given alone and in combination with artemether, in patients with uncomplicated falciparum malaria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8808179/),h,13.4,79984,DB00358,Mefloquine
,19641202,parasite clearance times,"The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001).",Artemisinin resistance in Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641202/),h,84,82896,DB00358,Mefloquine
,19641202,parasite clearance times,"The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001).",Artemisinin resistance in Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19641202/),h,48,82897,DB00358,Mefloquine
,12185558,time artem,The time artemisinin concentration stays above a minimum inhibitory concentration was estimated to 2.97 h (relative standard error 4.7 h).,Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185558/),h,2.97,84910,DB00358,Mefloquine
,12185558,concentration stays above a,The time artemisinin concentration stays above a minimum inhibitory concentration was estimated to 2.97 h (relative standard error 4.7 h).,Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185558/),h,2.97,84911,DB00358,Mefloquine
,12185558,minimum inhibitory concentration,The time artemisinin concentration stays above a minimum inhibitory concentration was estimated to 2.97 h (relative standard error 4.7 h).,Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185558/),h,2.97,84912,DB00358,Mefloquine
,12185558,oral clearance,"The two mefloquine enantiomers exhibited different pharmacokinetics, with an oral clearance of 3.51 (7.9) l/h and 0.602 (6.9) l/h for RS-mefloquine and SR-mefloquine, respectively.",Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185558/),[l] / [h],3.51,84913,DB00358,Mefloquine
,12185558,oral clearance,"The two mefloquine enantiomers exhibited different pharmacokinetics, with an oral clearance of 3.51 (7.9) l/h and 0.602 (6.9) l/h for RS-mefloquine and SR-mefloquine, respectively.",Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12185558/),[l] / [h],0.602,84914,DB00358,Mefloquine
,3555581,fever,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,61,87380,DB00358,Mefloquine
,3555581,parasite clearance times,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,61,87381,DB00358,Mefloquine
,3555581,parasite clearance times,"All patients responded to treatment with fever and parasite clearance times of 61 +/- 29 h (mean +/- s.d.) and 52 +/- 24 h, respectively.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,52,87382,DB00358,Mefloquine
,3555581,apparent absorption half-time (t1/2abs),The mean apparent absorption half-time (t1/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-1 (range 725-3368).,Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),h,4.89,87383,DB00358,Mefloquine
,3555581,peak plasma concentration,The mean apparent absorption half-time (t1/2abs) of mefloquine was 4.89 h (range 2.25-9.72) and mean peak plasma concentration was 1815 ng ml-1 (range 725-3368).,Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],1815,87384,DB00358,Mefloquine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],725,87385,DB00358,Mefloquine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],956,87386,DB00358,Mefloquine
,3555581,Peak plasma mefloquine concentrations,"Peak plasma mefloquine concentrations in three patients who vomited within 2 h of treatment were 725, 956 and 1972 ng ml-1.",Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3555581/),[ng] / [ml],1972,87387,DB00358,Mefloquine
,1674024,cure rate,The cure rate at 28 days was 70.8% (95% Cl 67-77.2%).,Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,70.8,91765,DB00358,Mefloquine
,1674024,Failure rates,"Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p less than 0.001).",Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,50,91766,DB00358,Mefloquine
,1674024,Failure rates,"Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p less than 0.001).",Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,29,91767,DB00358,Mefloquine
,1674024,Failure rates,"Failure rates were 50% in children under 6 years old, 29% in the 6-15 age group, and 19% in adults (p less than 0.001).",Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1674024/),%,19,91768,DB00358,Mefloquine
,26732683,half-life,"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),d,12.0,92972,DB00358,Mefloquine
,26732683,observed clearance (CL/f),"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),[l] / [h·kg],0.035,92973,DB00358,Mefloquine
,26732683,area-under-the-curve (AUC0→∞),"The mefloquine half-life, observed clearance (CL/f), and area-under-the-curve (AUC0→∞) were 12.0 days, 0.035 l/h/kg and 431 µg-h/ml, respectively.",Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26732683/),[µg-h] / [ml],431,92974,DB00358,Mefloquine
,21645370,maximum brain,The maximum brain (whole/free) concentrations of MQ were 1807/4.9 ng/g.,Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21645370/),[ng] / [g],1807,93815,DB00358,Mefloquine
,21645370,maximum brain,The maximum brain (whole/free) concentrations of MQ were 1807/4.9 ng/g.,Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21645370/),[ng] / [g],4.9,93816,DB00358,Mefloquine
,21645370,Maximum whole brain concentrations,Maximum whole brain concentrations of NGQMs were 23 - 21546 ng/g.,Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21645370/),[ng] / [g],23 - 21546,93817,DB00358,Mefloquine
,21645370,Maximum free brain concentrations,"Maximum free brain concentrations were 0.5 to 267 ng/g. Seven (28%) and two (8%) compounds exhibited acceptable whole and free brain concentrations, respectively.",Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21645370/),[ng] / [g],0.5 to 267,93818,DB00358,Mefloquine
,2338028,elimination half-life,"The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),d,11,97356,DB00358,Mefloquine
,2338028,total clearance,"The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),[ml] / [h·kg],45.8,97357,DB00358,Mefloquine
,2338028,apparent volume of distribution,"The pharmacokinetic parameters of elimination half-life, total clearance and apparent volume of distribution of M were 11 days, 45.8 ml/h.kg, and 14.8 l/kg, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),[l] / [kg],14.8,97358,DB00358,Mefloquine
,2338028,relative bioavailability,"The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),,0.98,97359,DB00358,Mefloquine
,2338028,relative bioavailability,"The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),,1.28,97360,DB00358,Mefloquine
,2338028,relative bioavailability,"The relative bioavailability of P, S, and M in the lacquered and non-lacquered tablet formulations in the 6 subjects studied were not significantly different with values (mean +/- SD) of 0.98 +/- 0.06, 1.28 +/- 0.20 and 1.02 +/- 0.17, respectively.",Pharmacokinetics of the combination pyrimethamine with sulfadoxine and mefloquine (FANSIMEF) in Chinese volunteers and the relative bioavailability of a lacquered tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338028/),,1.02,97361,DB00358,Mefloquine
,28526056,MIC,Pharmacokinetic simulations demonstrate that trough concentrations of TQ exceed the proposed MIC of 80 ng/ml in >95% of individuals.,The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526056/),[ng] / [ml],80,105394,DB00358,Mefloquine
,8256106,half-life,The mean half-life for L was 26 days.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),d,26,106680,DB00358,Mefloquine
,8256106,AUCs,The AUCs in the time interval 0-14 days for L varied between 19.3-31.5 mumol x days/l.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),[d·μM] / [l],19.3-31.5,106681,DB00358,Mefloquine
,8256106,trough concentrations,The range of trough concentrations at day 0 and 14 were 0.95-2.01 mumol/l for L and 1.69-5.62 mumol/l for the metabolite.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),[μM] / [l],0.95-2.01,106682,DB00358,Mefloquine
,8256106,trough concentrations,The range of trough concentrations at day 0 and 14 were 0.95-2.01 mumol/l for L and 1.69-5.62 mumol/l for the metabolite.,Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8256106/),[μM] / [l],1.69-5.62,106683,DB00358,Mefloquine
,24891429,exposure,"There was a trend of higher exposure to mefloquine in the pregnant women, but this difference did not reach statistical significance (656700 versus 542400 h × ng/mL; P=0.059).",Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24891429/),[h·ng] / [ml],656700,108088,DB00358,Mefloquine
,24891429,exposure,"There was a trend of higher exposure to mefloquine in the pregnant women, but this difference did not reach statistical significance (656700 versus 542400 h × ng/mL; P=0.059).",Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24891429/),[h·ng] / [ml],542400,108089,DB00358,Mefloquine
,24891429,total exposure,"However, the total exposure to carboxymefloquine was 49% lower during pregnancy (735600 versus 1499000 h × ng/mL; P<0.001) and the total drug exposure to artesunate was 42% higher during pregnancy (89.0 versus 62.9 h × ng/mL; P=0.039) compared with non-pregnant controls.",Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24891429/),[h·ng] / [ml],735600,108090,DB00358,Mefloquine
,24891429,total exposure,"However, the total exposure to carboxymefloquine was 49% lower during pregnancy (735600 versus 1499000 h × ng/mL; P<0.001) and the total drug exposure to artesunate was 42% higher during pregnancy (89.0 versus 62.9 h × ng/mL; P=0.039) compared with non-pregnant controls.",Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24891429/),[h·ng] / [ml],1499000,108091,DB00358,Mefloquine
,24891429,total drug exposure,"However, the total exposure to carboxymefloquine was 49% lower during pregnancy (735600 versus 1499000 h × ng/mL; P<0.001) and the total drug exposure to artesunate was 42% higher during pregnancy (89.0 versus 62.9 h × ng/mL; P=0.039) compared with non-pregnant controls.",Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24891429/),[h·ng] / [ml],89.0,108092,DB00358,Mefloquine
,24891429,total drug exposure,"However, the total exposure to carboxymefloquine was 49% lower during pregnancy (735600 versus 1499000 h × ng/mL; P<0.001) and the total drug exposure to artesunate was 42% higher during pregnancy (89.0 versus 62.9 h × ng/mL; P=0.039) compared with non-pregnant controls.",Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24891429/),[h·ng] / [ml],62.9,108093,DB00358,Mefloquine
,3499298,Excretion,Excretion of the unchanged drug and of its acid metabolite amounted respectively to 9% (5.2-13.1%) and 4.2% (2.9-6.2%) of the weekly dose.,Urinary excretion of mefloquine and some of its metabolites in African volunteers at steady state. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499298/),%,9,108199,DB00358,Mefloquine
,3499298,Excretion,Excretion of the unchanged drug and of its acid metabolite amounted respectively to 9% (5.2-13.1%) and 4.2% (2.9-6.2%) of the weekly dose.,Urinary excretion of mefloquine and some of its metabolites in African volunteers at steady state. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499298/),%,4.2,108200,DB00358,Mefloquine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],41.2,114191,DB00358,Mefloquine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],135,114192,DB00358,Mefloquine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],18.2,114193,DB00358,Mefloquine
,10761536,MICs,"The minimum inhibitory concentrations (MICs) of the equivalent concentrations (Eqs) of quinine or mefloquine, which completely inhibited the growth of the K1 strain of Plasmodium falciparum in vitro (MICs of quinine Eq and mefloquine Eq) were significantly lower in the sera of subjects on the combination regimens, than in the sera of subjects on mefloquine or quinine alone [MICs of quinine Eq: 41.2 (21.25-73.5) vs. 135 (118-150) ng/ml; MICs of mefloquine Eq: 18.2 (17-19.2) vs. 25.2 (24.4-26.8) ng/ml].",Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761536/),[ng] / [ml],25.2,114194,DB00358,Mefloquine
,1948262,maximum concentration,"Pharmacokinetic analysis revealed a mean maximum concentration of 420 +/- 141 ng/ml a time to peak concentration of 12 +/- 8 hours, terminal half-life was 14.93 +/- 4.43 days, apparent volume of distribution (Vd/f) was 16.5 +/- 5.6 l/kg and total clearance was 0.99 +/- 0.62 ml/min/kg.",Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1948262/),[ng] / [ml],420,115321,DB00358,Mefloquine
,1948262,time to peak concentration,"Pharmacokinetic analysis revealed a mean maximum concentration of 420 +/- 141 ng/ml a time to peak concentration of 12 +/- 8 hours, terminal half-life was 14.93 +/- 4.43 days, apparent volume of distribution (Vd/f) was 16.5 +/- 5.6 l/kg and total clearance was 0.99 +/- 0.62 ml/min/kg.",Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1948262/),h,12,115322,DB00358,Mefloquine
,1948262,terminal half-life,"Pharmacokinetic analysis revealed a mean maximum concentration of 420 +/- 141 ng/ml a time to peak concentration of 12 +/- 8 hours, terminal half-life was 14.93 +/- 4.43 days, apparent volume of distribution (Vd/f) was 16.5 +/- 5.6 l/kg and total clearance was 0.99 +/- 0.62 ml/min/kg.",Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1948262/),d,14.93,115323,DB00358,Mefloquine
,1948262,apparent volume of distribution (Vd/f),"Pharmacokinetic analysis revealed a mean maximum concentration of 420 +/- 141 ng/ml a time to peak concentration of 12 +/- 8 hours, terminal half-life was 14.93 +/- 4.43 days, apparent volume of distribution (Vd/f) was 16.5 +/- 5.6 l/kg and total clearance was 0.99 +/- 0.62 ml/min/kg.",Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1948262/),[l] / [kg],16.5,115324,DB00358,Mefloquine
,1948262,total clearance,"Pharmacokinetic analysis revealed a mean maximum concentration of 420 +/- 141 ng/ml a time to peak concentration of 12 +/- 8 hours, terminal half-life was 14.93 +/- 4.43 days, apparent volume of distribution (Vd/f) was 16.5 +/- 5.6 l/kg and total clearance was 0.99 +/- 0.62 ml/min/kg.",Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1948262/),[ml] / [kg·min],0.99,115325,DB00358,Mefloquine
,1948262,minimum whole blood mefloquine concentration,The mean minimum whole blood mefloquine concentration derived from this study was approximately 100 ng/ml which is considered to be low for treatment.,Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1948262/),[ng] / [ml],100,115326,DB00358,Mefloquine
,17884832,C(max),"Median values for C(max) (861 and 930 ng/mL), T(max) (1.5 and 1.5 h) and AUC(0-)(t) (2,050 and 2,470 ng.h/mL) were comparable for dihydroartemisinin in the two groups.",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),[ng] / [ml],861,115780,DB00358,Mefloquine
,17884832,C(max),"Median values for C(max) (861 and 930 ng/mL), T(max) (1.5 and 1.5 h) and AUC(0-)(t) (2,050 and 2,470 ng.h/mL) were comparable for dihydroartemisinin in the two groups.",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),[ng] / [ml],930,115781,DB00358,Mefloquine
,17884832,T(max),"Median values for C(max) (861 and 930 ng/mL), T(max) (1.5 and 1.5 h) and AUC(0-)(t) (2,050 and 2,470 ng.h/mL) were comparable for dihydroartemisinin in the two groups.",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),h,1.5,115782,DB00358,Mefloquine
,17884832,AUC(0-)(t),"Median values for C(max) (861 and 930 ng/mL), T(max) (1.5 and 1.5 h) and AUC(0-)(t) (2,050 and 2,470 ng.h/mL) were comparable for dihydroartemisinin in the two groups.",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),[h·ng] / [ml],"2,050",115783,DB00358,Mefloquine
,17884832,AUC(0-)(t),"Median values for C(max) (861 and 930 ng/mL), T(max) (1.5 and 1.5 h) and AUC(0-)(t) (2,050 and 2,470 ng.h/mL) were comparable for dihydroartemisinin in the two groups.",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),[h·ng] / [ml],"2,470",115784,DB00358,Mefloquine
,17884832,concentrations,"Exploratory analysis of mefloquine plasma levels revealed a trend towards higher concentrations in the younger age group during the absorption phase (2,550 and 1,815 ng/mL, 54 h after initiation of treatment, respectively).",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),,"2,550",115785,DB00358,Mefloquine
,17884832,concentrations,"Exploratory analysis of mefloquine plasma levels revealed a trend towards higher concentrations in the younger age group during the absorption phase (2,550 and 1,815 ng/mL, 54 h after initiation of treatment, respectively).",Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884832/),,"1,815",115786,DB00358,Mefloquine
,9850402,Cmax,"Mean Cmax was 108 micrograms/L (SD = 60, range 29-169), mean tlag was 0.3 h (SD = 0), mean tmax was 6.5 h (SD = 3.9, range 2-14).",The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850402/),[μg] / [l],108,121689,DB00358,Mefloquine
,9850402,tlag,"Mean Cmax was 108 micrograms/L (SD = 60, range 29-169), mean tlag was 0.3 h (SD = 0), mean tmax was 6.5 h (SD = 3.9, range 2-14).",The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850402/),h,0.3,121690,DB00358,Mefloquine
,9850402,tmax,"Mean Cmax was 108 micrograms/L (SD = 60, range 29-169), mean tlag was 0.3 h (SD = 0), mean tmax was 6.5 h (SD = 3.9, range 2-14).",The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850402/),h,6.5,121691,DB00358,Mefloquine
,9850402,bioavailability,"By comparing the area under the concentration-time curve with that found in a previous study on oral artemisinin, average bioavailability relative to oral administration was estimated to be approximately 30%.",The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850402/),%,30,121692,DB00358,Mefloquine
,9850402,parasite clearance time,Median parasite clearance time was 24 h (range 24-72).,The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850402/),h,24,121693,DB00358,Mefloquine
,8427948,blood to plasma ratio,"The blood to plasma ratio of the antimalarial mefloquine has been reported to be close to 1, while other reports indicate extensive accumulation in erythrocytes.",Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427948/),,1,127037,DB00358,Mefloquine
,8427948,blood to plasma ratio,The observed blood to plasma ratio of about 1 arises as the result of a balance between extensive red cell uptake and extensive plasma protein binding.,Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8427948/),,1,127038,DB00358,Mefloquine
,25377567,elimination half-life,Monte Carlo simulations predict that falciparum malaria infection is associated with a shorter elimination half-life (407 versus 566 h) and T>MIC (766 versus 893 h).,Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377567/),h,407,128771,DB00358,Mefloquine
,25377567,elimination half-life,Monte Carlo simulations predict that falciparum malaria infection is associated with a shorter elimination half-life (407 versus 566 h) and T>MIC (766 versus 893 h).,Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377567/),h,566,128772,DB00358,Mefloquine
,25377567,T>MIC,Monte Carlo simulations predict that falciparum malaria infection is associated with a shorter elimination half-life (407 versus 566 h) and T>MIC (766 versus 893 h).,Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377567/),h,766,128773,DB00358,Mefloquine
,25377567,T>MIC,Monte Carlo simulations predict that falciparum malaria infection is associated with a shorter elimination half-life (407 versus 566 h) and T>MIC (766 versus 893 h).,Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25377567/),h,893,128774,DB00358,Mefloquine
,16801402,half-life (t1/2),"The half-life (t1/2) of the carboxylic acid metabolite was estimated as 26 days, and the metabolite was eliminated more slowly than the parent drug (population t1/2 estimate, 10.5 days).",Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801402/),d,26,129470,DB00358,Mefloquine
,16801402,t1/2,"The half-life (t1/2) of the carboxylic acid metabolite was estimated as 26 days, and the metabolite was eliminated more slowly than the parent drug (population t1/2 estimate, 10.5 days).",Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16801402/),d,10.5,129471,DB00358,Mefloquine
,3069480,parasite clearance time,All the patients responded to treatment with a mean parasite clearance time of 66.6 h and a mean fever clearance time of 54.1 h.,A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3069480/),h,66.6,129564,DB00358,Mefloquine
,3069480,fever clearance time,All the patients responded to treatment with a mean parasite clearance time of 66.6 h and a mean fever clearance time of 54.1 h.,A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3069480/),h,54.1,129565,DB00358,Mefloquine
,3069480,terminal half-life (t1/2),"However, the terminal half-life (t1/2) and mean residence time (MRT) were shorter in the patients (12.2 vs 16.7 days for t1/2 and 15.5 vs 21.4 days for MRT).",A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3069480/),d,12.2,129566,DB00358,Mefloquine
,3069480,MRT,"However, the terminal half-life (t1/2) and mean residence time (MRT) were shorter in the patients (12.2 vs 16.7 days for t1/2 and 15.5 vs 21.4 days for MRT).",A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3069480/),d,15.5,129567,DB00358,Mefloquine
,3069480,MRT,"However, the terminal half-life (t1/2) and mean residence time (MRT) were shorter in the patients (12.2 vs 16.7 days for t1/2 and 15.5 vs 21.4 days for MRT).",A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3069480/),d,21.4,129568,DB00358,Mefloquine
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,82,134636,DB00358,Mefloquine
,8116811,parasite clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,81,134637,DB00358,Mefloquine
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,93,134638,DB00358,Mefloquine
,8116811,fever clearance time,"There were no significant differences in efficacy between halofantrine and Q7T7 (P > 0.1) as assessed by cure rate (92% versus 85%), mean parasite clearance time (82 hr versus 81 hr), or mean fever clearance time (93 hr versus 99 hr).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),h,99,134639,DB00358,Mefloquine
,8116811,side effects,"The side effects score was lower (2 versus 11; P < 0.001), there were less days on which side effects occurred (2.0 days versus 5.5 days; P < 0.001), and fewer patients had adverse effects on every treatment day (4% versus 42%; P < 0.01).",Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116811/),,2,134640,DB00358,Mefloquine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB00358,Mefloquine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB00358,Mefloquine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB00358,Mefloquine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB00358,Mefloquine
,1860148,fever clearance time,"In the 750-mg group, one patient exhibited an RII response, while the others responded to the treatment with a mean fever clearance time of 50.2 +/- 28.2 hours and a mean parasite clearance time of 70.2 +/- 17.3 hours.",Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860148/),h,50.2,135056,DB00358,Mefloquine
,1860148,parasite clearance time,"In the 750-mg group, one patient exhibited an RII response, while the others responded to the treatment with a mean fever clearance time of 50.2 +/- 28.2 hours and a mean parasite clearance time of 70.2 +/- 17.3 hours.",Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860148/),h,70.2,135057,DB00358,Mefloquine
,1860148,fever clearance time,"In the 1250-mg group, one patient exhibited an RII response, while the others responded to the treatment with a mean fever clearance time of 43.4 +/- 36.6 hours and a mean parasite clearance time of 73.4 +/- 25.2 hours.",Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860148/),h,43.4,135058,DB00358,Mefloquine
,1860148,parasite clearance time,"In the 1250-mg group, one patient exhibited an RII response, while the others responded to the treatment with a mean fever clearance time of 43.4 +/- 36.6 hours and a mean parasite clearance time of 73.4 +/- 25.2 hours.",Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1860148/),h,73.4,135059,DB00358,Mefloquine
,1820637,minimum concentration of,The mean minimum concentration of mefloquine at steady state ranged from 290 to 460 ng/ml.,Pharmacokinetics of prophylactic mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),[ng] / [ml],290 to 460,136257,DB00358,Mefloquine
,1820637,maximum concentration,The maximum concentration on week 16 after the last dose was 1558 +/- 48 ng/ml at the mean time of 38 +/- 19 hours.,Pharmacokinetics of prophylactic mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),[ng] / [ml],1558,136258,DB00358,Mefloquine
,1820637,absorption half life,The other pharmacokinetic parameters obtained were: absorption half life = 6.6 +/- 3.0 hours; distribution = 5.1 +/- 3.1 days; terminal half life = 12.9 +/- 2.2 days; apparent volume of distribution = 10.5 +/- 2.3 l/kg; area under the concentration-time curve = 26.9 +/- 2.2 mg/dl.,Pharmacokinetics of prophylactic mefloquine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),h,6.6,136259,DB00358,Mefloquine
,1820637,distribution,The other pharmacokinetic parameters obtained were: absorption half life = 6.6 +/- 3.0 hours; distribution = 5.1 +/- 3.1 days; terminal half life = 12.9 +/- 2.2 days; apparent volume of distribution = 10.5 +/- 2.3 l/kg; area under the concentration-time curve = 26.9 +/- 2.2 mg/dl.,Pharmacokinetics of prophylactic mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),d,5.1,136260,DB00358,Mefloquine
,1820637,terminal half life,The other pharmacokinetic parameters obtained were: absorption half life = 6.6 +/- 3.0 hours; distribution = 5.1 +/- 3.1 days; terminal half life = 12.9 +/- 2.2 days; apparent volume of distribution = 10.5 +/- 2.3 l/kg; area under the concentration-time curve = 26.9 +/- 2.2 mg/dl.,Pharmacokinetics of prophylactic mefloquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),d,12.9,136261,DB00358,Mefloquine
,1820637,apparent volume of distribution,The other pharmacokinetic parameters obtained were: absorption half life = 6.6 +/- 3.0 hours; distribution = 5.1 +/- 3.1 days; terminal half life = 12.9 +/- 2.2 days; apparent volume of distribution = 10.5 +/- 2.3 l/kg; area under the concentration-time curve = 26.9 +/- 2.2 mg/dl.,Pharmacokinetics of prophylactic mefloquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),[l] / [kg],10.5,136262,DB00358,Mefloquine
,1820637,area under the concentration-time curve,The other pharmacokinetic parameters obtained were: absorption half life = 6.6 +/- 3.0 hours; distribution = 5.1 +/- 3.1 days; terminal half life = 12.9 +/- 2.2 days; apparent volume of distribution = 10.5 +/- 2.3 l/kg; area under the concentration-time curve = 26.9 +/- 2.2 mg/dl.,Pharmacokinetics of prophylactic mefloquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820637/),[mg] / [dl],26.9,136263,DB00358,Mefloquine
,10750517,parasite clearance time (PCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),d,two,138310,DB00358,Mefloquine
,10750517,fever clearance time (FCT),The parasite clearance time (PCT) of these drugs ranged between two days and a week and the fever clearance time (FCT) was within 48 hours.,Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10750517/),h,48,138311,DB00358,Mefloquine
,9278194,CL/F,"CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1).",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),[l] / [h],6.5,140117,DB00358,Mefloquine
,9278194,V(ss)/F,"CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1).",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),l,815,140118,DB00358,Mefloquine
,9278194,k,"CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1).",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),1/[h],0.0081,140119,DB00358,Mefloquine
,9278194,oral clearance,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),[l] / [h],0.92,140120,DB00358,Mefloquine
,9278194,oral clearance,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),[l] / [h],2.14,140121,DB00358,Mefloquine
,9278194,half-life,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),h,345,140122,DB00358,Mefloquine
,9278194,half-life,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),h,185,140123,DB00358,Mefloquine
,9278194,Urinary recovery of unchanged substance,Urinary recovery of unchanged substance was 8.7% for (+)RS-MQ and 12.3% for (-)SR-MQ.,Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),%,8.7,140124,DB00358,Mefloquine
,9278194,Urinary recovery of unchanged substance,Urinary recovery of unchanged substance was 8.7% for (+)RS-MQ and 12.3% for (-)SR-MQ.,Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),%,12.3,140125,DB00358,Mefloquine
,30198595,minimum plasma concentration,"However, all scenarios suggest that a dose of 62.5 mg weekly achieves or exceeds the exposure in adults following a 250 mg weekly dose and results in a minimum plasma concentration of 620 ng ml-1 , which is considered necessary to achieve 95% prophylactic efficacy.",Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198595/),[ng] / [ml],620,140651,DB00358,Mefloquine
,7974678,Peak mefloquine concentrations,"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[ng] / [ml],1257,143704,DB00358,Mefloquine
,7974678,Peak mefloquine concentrations,"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[ng] / [ml],1617,143705,DB00358,Mefloquine
,7974678,total apparent volume of distribution (Vd/f),"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[l] / [kg],10.8,143706,DB00358,Mefloquine
,7974678,total apparent volume of distribution (Vd/f),"Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution (Vd/f) was larger (10.8 [8.3-26.1] vs. 10.0 [4.8-13.9] L/kg; P < 0.05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy.",Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974678/),[l] / [kg],10.0,143707,DB00358,Mefloquine
,32521771,peak plasma concentration (Cmax),The peak plasma concentration (Cmax) after a single oral dose of mefloquine was 2.71 ug/mL and time to reach Cmax (Tmax) was 15 h.,Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32521771/),[ug] / [ml],2.71,144959,DB00358,Mefloquine
,32521771,time to reach Cmax (Tmax),The peak plasma concentration (Cmax) after a single oral dose of mefloquine was 2.71 ug/mL and time to reach Cmax (Tmax) was 15 h.,Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32521771/),h,15,144960,DB00358,Mefloquine
,32521771,elimination half-life,The elimination half-life was 224 h.,Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32521771/),h,224,144961,DB00358,Mefloquine
,9403285,Cmax,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[μg] / [l],1500,146846,DB00358,Mefloquine
,9403285,Cmax,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[μg] / [l],868,146847,DB00358,Mefloquine
,9403285,AUC,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[h·mg] / [l],645,146848,DB00358,Mefloquine
,9403285,AUC,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[h·mg] / [l],461,146849,DB00358,Mefloquine
,9403285,Cmax,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[μg] / [l],1662,146850,DB00358,Mefloquine
,9403285,Cmax,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[μg] / [l],1231,146851,DB00358,Mefloquine
,9403285,AUC,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[h·mg] / [l],1740,146852,DB00358,Mefloquine
,9403285,AUC,"The parameters Cmax and AUC of both mefloquine and its metabolite were significantly (P < 0.05) higher under post-prandial conditions than under fasting conditions (mefloquine: mean Cmax 1500 vs 868 micrograms.l-1, mean AUC 645 vs 461 mg l-1.h; metabolite: Cmax 1662 vs 1231 micrograms.l-1, AUC 1740 vs 1310 mg l-1.h).",Food increases the bioavailability of mefloquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),[h·mg] / [l],1310,146853,DB00358,Mefloquine
,9403285,time to peak plasma concentration,The time to peak plasma concentration of mefloquine was significantly shorter after food intake (17 vs 36 h).,Food increases the bioavailability of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),h,17,146854,DB00358,Mefloquine
,9403285,time to peak plasma concentration,The time to peak plasma concentration of mefloquine was significantly shorter after food intake (17 vs 36 h).,Food increases the bioavailability of mefloquine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403285/),h,36,146855,DB00358,Mefloquine
,9452284,times to fever clearance,Mean [range] times to fever clearance of the two groups were similar (42 hr [15-104] versus 42 hr [6-119]).,Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,42,152695,DB00358,Mefloquine
,9452284,times to fever clearance,Mean [range] times to fever clearance of the two groups were similar (42 hr [15-104] versus 42 hr [6-119]).,Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,42,152696,DB00358,Mefloquine
,9452284,times to,Artesunate suppositories resulted in significantly longer times to achieve 50% and 90% reductions of the initial parasite counts (17 and 26 hr versus 9 and 15 hr; P < 0.05 and P < 0.001).,Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,17,152697,DB00358,Mefloquine
,9452284,times to,Artesunate suppositories resulted in significantly longer times to achieve 50% and 90% reductions of the initial parasite counts (17 and 26 hr versus 9 and 15 hr; P < 0.05 and P < 0.001).,Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,26,152698,DB00358,Mefloquine
,9452284,times to,Artesunate suppositories resulted in significantly longer times to achieve 50% and 90% reductions of the initial parasite counts (17 and 26 hr versus 9 and 15 hr; P < 0.05 and P < 0.001).,Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,9,152699,DB00358,Mefloquine
,9452284,times to,Artesunate suppositories resulted in significantly longer times to achieve 50% and 90% reductions of the initial parasite counts (17 and 26 hr versus 9 and 15 hr; P < 0.05 and P < 0.001).,Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,15,152700,DB00358,Mefloquine
,9452284,Time,"Time [range] to parasite clearance was longer in the artesunate suppositories group (42 hr [14-93] versus 35 hr [16-69]), but the difference was not significant.",Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,42,152701,DB00358,Mefloquine
,9452284,Time,"Time [range] to parasite clearance was longer in the artesunate suppositories group (42 hr [14-93] versus 35 hr [16-69]), but the difference was not significant.",Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452284/),h,35,152702,DB00358,Mefloquine
above,32438446,Cmax /EC90 ratio,Only 14 of the 56 analyzed drugs achieved a Cmax /EC90 ratio above 1.,Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438446/),,1,152820,DB00358,Mefloquine
,2390434,time from dose administration to peak whole blood mefloquine concentration,3. The median time from dose administration to peak whole blood mefloquine concentration was 6 (range 3-24) h.,Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),h,6,152971,DB00358,Mefloquine
,2390434,peak,"Mean (+/- s.d.) peak and trough concentrations in the seventh week were 722 +/- 279 and 488 +/- 155 ng ml-1 with the 250 mg/week dose, and 390 +/- 81 and 185 +/- 53 ng ml-1 with the 125 mg/week dose regimens respectively.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),[ng] / [ml],722,152972,DB00358,Mefloquine
,2390434,peak,"Mean (+/- s.d.) peak and trough concentrations in the seventh week were 722 +/- 279 and 488 +/- 155 ng ml-1 with the 250 mg/week dose, and 390 +/- 81 and 185 +/- 53 ng ml-1 with the 125 mg/week dose regimens respectively.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),[ng] / [ml],390,152973,DB00358,Mefloquine
,2390434,trough concentrations,"Mean (+/- s.d.) peak and trough concentrations in the seventh week were 722 +/- 279 and 488 +/- 155 ng ml-1 with the 250 mg/week dose, and 390 +/- 81 and 185 +/- 53 ng ml-1 with the 125 mg/week dose regimens respectively.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),[ng] / [ml],488,152974,DB00358,Mefloquine
,2390434,trough concentrations,"Mean (+/- s.d.) peak and trough concentrations in the seventh week were 722 +/- 279 and 488 +/- 155 ng ml-1 with the 250 mg/week dose, and 390 +/- 81 and 185 +/- 53 ng ml-1 with the 125 mg/week dose regimens respectively.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),[ng] / [ml],390,152975,DB00358,Mefloquine
,2390434,trough concentrations,"Mean (+/- s.d.) peak and trough concentrations in the seventh week were 722 +/- 279 and 488 +/- 155 ng ml-1 with the 250 mg/week dose, and 390 +/- 81 and 185 +/- 53 ng ml-1 with the 125 mg/week dose regimens respectively.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),[ng] / [ml],185,152976,DB00358,Mefloquine
,2390434,clearance (CL/F),"Mean (+/- s.d.) clearance (CL/F) was 0.78 +/- 0.27 ml min-1 kg-1, and the apparent terminal elimination half-life (t1/2) was 11.6 +/- 7.9 days.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),[ml] / [kg·min],0.78,152977,DB00358,Mefloquine
,2390434,apparent terminal elimination half-life (t1/2),"Mean (+/- s.d.) clearance (CL/F) was 0.78 +/- 0.27 ml min-1 kg-1, and the apparent terminal elimination half-life (t1/2) was 11.6 +/- 7.9 days.",Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390434/),d,11.6,152978,DB00358,Mefloquine
,10890135,Cmax,"After the fifth dose, mean Cmax in females reached 1692 ng/ml (4.48 mumol/l), equivalent to a high therapeutic concentration.",Mefloquine concentration profiles during prophylactic dose regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10890135/),[ng] / [ml],1692,153684,DB00358,Mefloquine
,10890135,Cmax,"After the fifth dose, mean Cmax in females reached 1692 ng/ml (4.48 mumol/l), equivalent to a high therapeutic concentration.",Mefloquine concentration profiles during prophylactic dose regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10890135/),[μM] / [l],4.48,153685,DB00358,Mefloquine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,3.4,156476,DB00358,Mefloquine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,5.8,156477,DB00358,Mefloquine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,0.15,156478,DB00358,Mefloquine
,10426558,Ki,"The mefloquine Ki of metoprolol alpha-hydroxylation and O-demethylation were 3.4 and 5.8 microM respectively, whereas those of halofantrine were 0.15 and 0.32 microM respectively.","In vitro effects of racemates, separate enantiomers and major metabolites of mefloquine and halofantrine on metoprolol biotransformation by rat liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426558/),μM,0.32,156479,DB00358,Mefloquine
,8799526,parasite clearance time (PCT),"3. Treatment with the artemisinin/mefloquine combination resulted in a shorter parasite clearance time (PCT) of 24 (22, 27; 95% confidence interval) h vs 31 (27, 36) h and fever subsidence time (FST) of 14 (12, 16) h vs 20 (18, 23) h compared with artemisinin monotherapy.",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),h,24,158658,DB00358,Mefloquine
,8799526,parasite clearance time (PCT),"3. Treatment with the artemisinin/mefloquine combination resulted in a shorter parasite clearance time (PCT) of 24 (22, 27; 95% confidence interval) h vs 31 (27, 36) h and fever subsidence time (FST) of 14 (12, 16) h vs 20 (18, 23) h compared with artemisinin monotherapy.",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),h,31,158659,DB00358,Mefloquine
,8799526,fever subsidence time (FST),"3. Treatment with the artemisinin/mefloquine combination resulted in a shorter parasite clearance time (PCT) of 24 (22, 27; 95% confidence interval) h vs 31 (27, 36) h and fever subsidence time (FST) of 14 (12, 16) h vs 20 (18, 23) h compared with artemisinin monotherapy.",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),h,14,158660,DB00358,Mefloquine
,8799526,fever subsidence time (FST),"3. Treatment with the artemisinin/mefloquine combination resulted in a shorter parasite clearance time (PCT) of 24 (22, 27; 95% confidence interval) h vs 31 (27, 36) h and fever subsidence time (FST) of 14 (12, 16) h vs 20 (18, 23) h compared with artemisinin monotherapy.",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),h,20,158661,DB00358,Mefloquine
,8799526,maximum plasma concentrations (Cmax),4. The maximum plasma concentrations (Cmax) were similar after artemisinin monotherapy (615.4 +/- 387.0 ng ml-1) and in combination with mefloquine (851.8 +/- 523.6 ng ml-1).,Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),[ng] / [ml],615.4,158662,DB00358,Mefloquine
,8799526,maximum plasma concentrations (Cmax),4. The maximum plasma concentrations (Cmax) were similar after artemisinin monotherapy (615.4 +/- 387.0 ng ml-1) and in combination with mefloquine (851.8 +/- 523.6 ng ml-1).,Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),[ng] / [ml],851.8,158663,DB00358,Mefloquine
,8799526,Elimination half-lives (t1/2),"Elimination half-lives (t1/2) were also identical at 2.2 +/- 0.6 h and 2.5 +/- 0.7 h, respectively.",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),h,2.2,158664,DB00358,Mefloquine
,8799526,Elimination half-lives (t1/2),"Elimination half-lives (t1/2) were also identical at 2.2 +/- 0.6 h and 2.5 +/- 0.7 h, respectively.",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),h,2.5,158665,DB00358,Mefloquine
,8799526,AUC,"However, the AUC values were higher (P < 0.05) after combination therapy (3252 +/- 1873 ng ml-1 h) than after monotherapy (2234 +/- 1502 ng ml-1 h).",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),[h·ng] / [ml],3252,158666,DB00358,Mefloquine
,8799526,AUC,"However, the AUC values were higher (P < 0.05) after combination therapy (3252 +/- 1873 ng ml-1 h) than after monotherapy (2234 +/- 1502 ng ml-1 h).",Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),[h·ng] / [ml],2234,158667,DB00358,Mefloquine
,8799526,oral clearance,The oral clearance values were lower (P < 0.05) after combination therapy (195.4 +/- 86.9 l h-1) than after monotherapy (314.3 +/- 189.4 l h-1).,Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),[l] / [h],195.4,158668,DB00358,Mefloquine
,8799526,oral clearance,The oral clearance values were lower (P < 0.05) after combination therapy (195.4 +/- 86.9 l h-1) than after monotherapy (314.3 +/- 189.4 l h-1).,Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799526/),[l] / [h],314.3,158669,DB00358,Mefloquine
,30012152,half-life,"The mefloquine half-life was 10.25 days, the maximum concentration (Cmax) was 2.53 µg/ml, the area-under-the-curve (AUC0-∞) was 359 µg/ml h, the observed clearance (Cl/f) was 0.045 l/kg/h and the volume of distribution (V/f) was 14.6 l/kg.",Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012152/),d,10.25,160649,DB00358,Mefloquine
,30012152,maximum concentration (Cmax),"The mefloquine half-life was 10.25 days, the maximum concentration (Cmax) was 2.53 µg/ml, the area-under-the-curve (AUC0-∞) was 359 µg/ml h, the observed clearance (Cl/f) was 0.045 l/kg/h and the volume of distribution (V/f) was 14.6 l/kg.",Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012152/),[μg] / [ml],2.53,160650,DB00358,Mefloquine
,30012152,area-under-the-curve (AUC0-∞),"The mefloquine half-life was 10.25 days, the maximum concentration (Cmax) was 2.53 µg/ml, the area-under-the-curve (AUC0-∞) was 359 µg/ml h, the observed clearance (Cl/f) was 0.045 l/kg/h and the volume of distribution (V/f) was 14.6 l/kg.",Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012152/),[μg] / [h·ml],359,160651,DB00358,Mefloquine
,30012152,clearance (Cl/f),"The mefloquine half-life was 10.25 days, the maximum concentration (Cmax) was 2.53 µg/ml, the area-under-the-curve (AUC0-∞) was 359 µg/ml h, the observed clearance (Cl/f) was 0.045 l/kg/h and the volume of distribution (V/f) was 14.6 l/kg.",Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012152/),[l] / [h·kg],0.045,160652,DB00358,Mefloquine
,30012152,volume of distribution (V/f),"The mefloquine half-life was 10.25 days, the maximum concentration (Cmax) was 2.53 µg/ml, the area-under-the-curve (AUC0-∞) was 359 µg/ml h, the observed clearance (Cl/f) was 0.045 l/kg/h and the volume of distribution (V/f) was 14.6 l/kg.",Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012152/),[l] / [kg],14.6,160653,DB00358,Mefloquine
,22369125,Extraction recoveries,Extraction recoveries of mefloquine in plasma or saliva were 76-86% or 83-93% respectively.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),%,76-86,161593,DB00358,Mefloquine
,22369125,Extraction recoveries,Extraction recoveries of mefloquine in plasma or saliva were 76-86% or 83-93% respectively.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),%,83-93,161594,DB00358,Mefloquine
,22369125,Limit of quantification,Limit of quantification of mefloquine was 20 ng/ml.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),[ng] / [ml],20,161595,DB00358,Mefloquine
,22369125,Saliva:plasma concentrations ratio,Saliva:plasma concentrations ratio was 0.42.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),,0.42,161596,DB00358,Mefloquine
,24117456,elimination half-life,"However, it has low solubility in water, a long elimination half-life (4 days), and is neurotoxic, which leads to unwanted side effects.",Formulation and evaluation of Pheroid vesicles containing mefloquine for the treatment of malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24117456/),d,4,171514,DB00358,Mefloquine
,12641404,fever subsidence times,The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever subsidence times of (31.5 +/- 10.1 hours) and (31.4 +/- 11.1 hours).,Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12641404/),h,31.4,175608,DB00358,Mefloquine
,2789071,Maximum blood,"Maximum blood and plasma M concentrations of 1872 +/- 362 ng ml-1 (mean +/- s.d.) and 1900 +/- 434 ng ml-1, respectively, were found within 6-10 h after the second dose.",Divided-dose kinetics of mefloquine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789071/),[ng] / [ml],1872,175683,DB00358,Mefloquine
,2789071,plasma M concentrations,"Maximum blood and plasma M concentrations of 1872 +/- 362 ng ml-1 (mean +/- s.d.) and 1900 +/- 434 ng ml-1, respectively, were found within 6-10 h after the second dose.",Divided-dose kinetics of mefloquine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789071/),[ng] / [ml],1900,175684,DB00358,Mefloquine
,2789071,terminal plasma elimination half-life,The terminal plasma elimination half-life was 20.1 +/- 3.7 days (mean +/- s.d.) and the oral clearance was 22.3 +/- 6.7 ml h-1 kg-1 (mean +/- s.d.).,Divided-dose kinetics of mefloquine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789071/),d,20.1,175685,DB00358,Mefloquine
,2789071,oral clearance,The terminal plasma elimination half-life was 20.1 +/- 3.7 days (mean +/- s.d.) and the oral clearance was 22.3 +/- 6.7 ml h-1 kg-1 (mean +/- s.d.).,Divided-dose kinetics of mefloquine in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789071/),[ml] / [h·kg],22.3,175686,DB00358,Mefloquine
,1596283,IC50,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,7.5,176859,DB00358,Mefloquine
,1596283,Ki,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,11.2,176860,DB00358,Mefloquine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,17.5,176861,DB00358,Mefloquine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,122,176862,DB00358,Mefloquine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,8.6,176863,DB00358,Mefloquine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,28.5,176864,DB00358,Mefloquine
,28363636,peak plasma concentration (Cmax),"The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),[ng] / [ml],1310,181155,DB00358,Mefloquine
,28363636,peak plasma concentration (Cmax),"The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),[ng] / [ml],34 800,181156,DB00358,Mefloquine
,28363636,time (tmax),"The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,1·5,181157,DB00358,Mefloquine
,28363636,time (tmax),"The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,4,181158,DB00358,Mefloquine
,28363636,elimination half-life,"The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,86,181159,DB00358,Mefloquine
,28363636,elimination half-life,"The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1·5 h and 4 h, with a mean elimination half-life between 86 h and 118 h.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,118,181160,DB00358,Mefloquine
,28363636,log10 parasite reduction ratio,"In part 2, the log10 parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),,1·55,181161,DB00358,Mefloquine
,28363636,log10 parasite reduction ratio,"In part 2, the log10 parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),,2·34,181162,DB00358,Mefloquine
,28363636,parasite,"In part 2, the log10 parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,9·4,181163,DB00358,Mefloquine
,28363636,clearance half-life,"In part 2, the log10 parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,9·4,181164,DB00358,Mefloquine
,28363636,clearance half-life,"In part 2, the log10 parasite reduction ratio at 48 h in the DSM265 (150 mg) group was 1·55 (95% CI 1·42-1·67) and in the mefloquine (10 mg/kg) group was 2·34 (2·17-2·52), corresponding to a parasite clearance half-life of 9·4 h (8·7-10·2) and 6·2 h (5·7-6·7), respectively.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),h,6·2,181165,DB00358,Mefloquine
,28363636,minimum inhibitory concentration,"The median minimum inhibitory concentration of DSM265 in blood was estimated as 1040 ng/mL (range 552-1500), resulting in a predicted single efficacious dose of 340 mg.","Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363636/),[ng] / [ml],1040,181166,DB00358,Mefloquine
,1483498,maximum whole blood mefloquine concentration,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[ng] / [ml],1600,183339,DB00358,Mefloquine
,1483498,maximum whole blood mefloquine concentration,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[ng] / [ml],1160,183340,DB00358,Mefloquine
,1483498,terminal half-life,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,14.4,183341,DB00358,Mefloquine
,1483498,terminal half-life,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,19.3,183342,DB00358,Mefloquine
,1483498,mean residence time,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,11.9,183343,DB00358,Mefloquine
,1483498,mean residence time,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),d,16.0,183344,DB00358,Mefloquine
,1483498,volume of distribution at steady state,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[1] / [kg],13.3,183345,DB00358,Mefloquine
,1483498,volume of distribution at steady state,"There was a significantly higher maximum whole blood mefloquine concentration after coadministration with tetracycline (1600 vs 1160 ng.ml-1), as well as a significantly reduced terminal half-life (14.4 vs 19.3 days), mean residence time (11.9 vs 16.0 days) and volume of distribution at steady state (13.3 vs 19.9 1.kg-1).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[1] / [kg],19.9,183346,DB00358,Mefloquine
,1483498,AUC from zero time to infinity,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 7 days was significantly increased by tetracycline (6.18 vs 4.76 micrograms.ml-1.day).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[d·μg] / [ml],6.18,183347,DB00358,Mefloquine
,1483498,AUC from zero time to 7 days,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 7 days was significantly increased by tetracycline (6.18 vs 4.76 micrograms.ml-1.day).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[d·μg] / [ml],6.18,183348,DB00358,Mefloquine
,1483498,AUC from zero time to 7 days,"Although there was no significant change in the AUC from zero time to infinity, the AUC from zero time to 7 days was significantly increased by tetracycline (6.18 vs 4.76 micrograms.ml-1.day).",Effect of tetracycline on mefloquine pharmacokinetics in Thai males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1483498/),[d·μg] / [ml],4.76,183349,DB00358,Mefloquine
,24886117,absorption rate constant,"Mean parameter estimates (% inter-individual variability) were as follows: 0.16 h(-1) (75%) for the absorption rate constant, 1.13 L/h (30%) for the apparent plasma clearance, 271 L (21%) for the apparent central distribution volume, 344 L (54%) for the apparent peripheral distribution volume, and 1.43 L/h for the apparent distribution clearance.","Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24886117/),1/[h],0.16,184327,DB00358,Mefloquine
,24886117,apparent plasma clearance,"Mean parameter estimates (% inter-individual variability) were as follows: 0.16 h(-1) (75%) for the absorption rate constant, 1.13 L/h (30%) for the apparent plasma clearance, 271 L (21%) for the apparent central distribution volume, 344 L (54%) for the apparent peripheral distribution volume, and 1.43 L/h for the apparent distribution clearance.","Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24886117/),[l] / [h],1.13,184328,DB00358,Mefloquine
,24886117,apparent central distribution volume,"Mean parameter estimates (% inter-individual variability) were as follows: 0.16 h(-1) (75%) for the absorption rate constant, 1.13 L/h (30%) for the apparent plasma clearance, 271 L (21%) for the apparent central distribution volume, 344 L (54%) for the apparent peripheral distribution volume, and 1.43 L/h for the apparent distribution clearance.","Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24886117/),l,271,184329,DB00358,Mefloquine
,24886117,apparent peripheral distribution volume,"Mean parameter estimates (% inter-individual variability) were as follows: 0.16 h(-1) (75%) for the absorption rate constant, 1.13 L/h (30%) for the apparent plasma clearance, 271 L (21%) for the apparent central distribution volume, 344 L (54%) for the apparent peripheral distribution volume, and 1.43 L/h for the apparent distribution clearance.","Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24886117/),l,344,184330,DB00358,Mefloquine
,24886117,apparent distribution clearance,"Mean parameter estimates (% inter-individual variability) were as follows: 0.16 h(-1) (75%) for the absorption rate constant, 1.13 L/h (30%) for the apparent plasma clearance, 271 L (21%) for the apparent central distribution volume, 344 L (54%) for the apparent peripheral distribution volume, and 1.43 L/h for the apparent distribution clearance.","Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24886117/),[l] / [h],1.43,184331,DB00358,Mefloquine
,874785,sensitivity,The sensitivity of the assays for mefloquine was 0.05 microgram/ml of whole blood or plasma and 0.25 microgram/ml of urine using 5-ml samples.,"Quantitation of the antimalarial agent, mefloquine, in blood, plasma, and urine using high-pressure liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/874785/),[μg] / [ml],0.05,186057,DB00358,Mefloquine
,874785,sensitivity,The sensitivity of the assays for mefloquine was 0.05 microgram/ml of whole blood or plasma and 0.25 microgram/ml of urine using 5-ml samples.,"Quantitation of the antimalarial agent, mefloquine, in blood, plasma, and urine using high-pressure liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/874785/),[μg] / [ml],0.25,186058,DB00358,Mefloquine
,33028,elimination t1/2,"The elimination t1/2 of unchanged drug after oral or intraperitoneal dosing was 18.7 and 13.5 hr, respectively, for urine and 14.5 and 15.4 hr, respectively, for feces.","The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33028/),h,18.7,186453,DB00358,Mefloquine
,33028,elimination t1/2,"The elimination t1/2 of unchanged drug after oral or intraperitoneal dosing was 18.7 and 13.5 hr, respectively, for urine and 14.5 and 15.4 hr, respectively, for feces.","The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33028/),h,13.5,186454,DB00358,Mefloquine
,33028,elimination t1/2,"The elimination t1/2 of unchanged drug after oral or intraperitoneal dosing was 18.7 and 13.5 hr, respectively, for urine and 14.5 and 15.4 hr, respectively, for feces.","The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33028/),h,14.5,186455,DB00358,Mefloquine
,33028,elimination t1/2,"The elimination t1/2 of unchanged drug after oral or intraperitoneal dosing was 18.7 and 13.5 hr, respectively, for urine and 14.5 and 15.4 hr, respectively, for feces.","The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33028/),h,15.4,186456,DB00358,Mefloquine
,33028,t1/2,The t1/2 of parent drug after oral administration was 17.0 hr for plasma and 18.6 hr for erythrocytes.,"The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33028/),h,17.0,186457,DB00358,Mefloquine
,33028,t1/2,The t1/2 of parent drug after oral administration was 17.0 hr for plasma and 18.6 hr for erythrocytes.,"The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33028/),h,18.6,186458,DB00358,Mefloquine
,6750530,whole blood half-life,"Tolerance and pharmacokinetic evaluated in 8 black African subjects, is according to previously studies in American or Asian patients: the mean whole blood half-life is 15,6 days.",[Mefloquine in the treatment and prevention of malaria ]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6750530/),d,"15,6",188842,DB00358,Mefloquine
,19358697,terminal half-life,All three MQ formulations had a terminal half-life of 14-15 days and time to maximum plasma concentration of 45-52 hours.,Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358697/),d,14-15,193719,DB00358,Mefloquine
,19358697,time to maximum plasma concentration,All three MQ formulations had a terminal half-life of 14-15 days and time to maximum plasma concentration of 45-52 hours.,Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358697/),h,45-52,193720,DB00358,Mefloquine
,19358697,maximal concentration (Cmax),"The maximal concentration (Cmax) and interquartile range was 2,820 ng/ml (2,614-3,108) for Lariam, 2,500 ng/ml (2,363-2,713) for Mephaquin, and 2,750 ng/ml (2,550-3,000) for Mefloquina AC Farma.",Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358697/),[ng] / [ml],"2,820",193721,DB00358,Mefloquine
,19358697,maximal concentration (Cmax),"The maximal concentration (Cmax) and interquartile range was 2,820 ng/ml (2,614-3,108) for Lariam, 2,500 ng/ml (2,363-2,713) for Mephaquin, and 2,750 ng/ml (2,550-3,000) for Mefloquina AC Farma.",Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358697/),[ng] / [ml],"2,500",193722,DB00358,Mefloquine
,19358697,maximal concentration (Cmax),"The maximal concentration (Cmax) and interquartile range was 2,820 ng/ml (2,614-3,108) for Lariam, 2,500 ng/ml (2,363-2,713) for Mephaquin, and 2,750 ng/ml (2,550-3,000) for Mefloquina AC Farma.",Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358697/),[ng] / [ml],"2,750",193723,DB00358,Mefloquine
,23836173,t1/2,"Considerable changes were observed for mefloquine, with a 5-fold increase of t1/2 (182.7 h versus 33.6 h) and 2-fold increase of AUC (1,116,517.8 ng · h/ml versus 522,409.1 ng · h/ml).",Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23836173/),h,182.7,199432,DB00358,Mefloquine
,23836173,t1/2,"Considerable changes were observed for mefloquine, with a 5-fold increase of t1/2 (182.7 h versus 33.6 h) and 2-fold increase of AUC (1,116,517.8 ng · h/ml versus 522,409.1 ng · h/ml).",Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23836173/),h,33.6,199433,DB00358,Mefloquine
,23836173,AUC,"Considerable changes were observed for mefloquine, with a 5-fold increase of t1/2 (182.7 h versus 33.6 h) and 2-fold increase of AUC (1,116,517.8 ng · h/ml versus 522,409.1 ng · h/ml).",Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23836173/),[h·ng] / [ml],"1,116,517.8",199434,DB00358,Mefloquine
,23836173,AUC,"Considerable changes were observed for mefloquine, with a 5-fold increase of t1/2 (182.7 h versus 33.6 h) and 2-fold increase of AUC (1,116,517.8 ng · h/ml versus 522,409.1 ng · h/ml).",Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23836173/),[h·ng] / [ml],"522,409.1",199435,DB00358,Mefloquine
,3493885,elimination half-life,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),h,123,200019,DB00358,Mefloquine
,3493885,elimination half-life,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),h,179,200020,DB00358,Mefloquine
,3493885,elimination half-life,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),h,550,200021,DB00358,Mefloquine
,3493885,volume of distribution,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[1] / [kg],2.5,200022,DB00358,Mefloquine
,3493885,volume of distribution,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[1] / [kg],0.15,200023,DB00358,Mefloquine
,3493885,volume of distribution,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[1] / [kg],18.6,200024,DB00358,Mefloquine
,3493885,total systemic clearance,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[ml] / [h·kg],14.0,200025,DB00358,Mefloquine
,3493885,total systemic clearance,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[ml] / [h·kg],0.64,200026,DB00358,Mefloquine
,3493885,total systemic clearance,"After the last maintenance dose the following kinetic parameters were determined for pyrimethamine, sulfadoxine and mefloquine, respectively: elimination half-life = 123, 179 and 550 h; volume of distribution in the postdistributive phase = 2.5, 0.15 and 18.6 1 X kg-1, and total systemic clearance = 14.0, 0.64 and 24.0 ml X h-1 X kg-1.",Multiple-dose pharmacokinetics of the antimalarial drug Fansimef (pyrimethamine + sulfadoxine + mefloquine) in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3493885/),[ml] / [h·kg],24.0,200027,DB00358,Mefloquine
,3608626,S,"Following administration of Fansimef all three components revealed long elimination half-lives (P = 88 h, S = 183 h, M = 437 h) and high binding to plasma proteins (P = 92.5%, S = 87.6%, M = 97.6%).",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),h,183,200145,DB00358,Mefloquine
,3608626,S,"Following administration of Fansimef all three components revealed long elimination half-lives (P = 88 h, S = 183 h, M = 437 h) and high binding to plasma proteins (P = 92.5%, S = 87.6%, M = 97.6%).",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),h,437,200146,DB00358,Mefloquine
,3608626,apparent volume of distribution in the postdistributive phase (VD beta/F),The apparent volume of distribution in the postdistributive phase (VD beta/F) was small for S (0.13 l/kg) but amounted to 2.1 l/kg for P and reached even 11.8 l/kg in the case of M.,Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[l] / [kg],0.13,200147,DB00358,Mefloquine
,3608626,apparent volume of distribution in the postdistributive phase (VD beta/F),The apparent volume of distribution in the postdistributive phase (VD beta/F) was small for S (0.13 l/kg) but amounted to 2.1 l/kg for P and reached even 11.8 l/kg in the case of M.,Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[l] / [kg],2.1,200148,DB00358,Mefloquine
,3608626,apparent volume of distribution in the postdistributive phase (VD beta/F),The apparent volume of distribution in the postdistributive phase (VD beta/F) was small for S (0.13 l/kg) but amounted to 2.1 l/kg for P and reached even 11.8 l/kg in the case of M.,Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[l] / [kg],11.8,200149,DB00358,Mefloquine
,3608626,systemic clearance (ClTS/F),"The systemic clearance (ClTS/F) showed almost identical values for P and M, namely approximately equal to 19 ml/h/kg, while sulfadoxine reached only a value of 0.5 ml/h/kg.",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[ml] / [h·kg],19,200150,DB00358,Mefloquine
,3608626,systemic clearance (ClTS/F),"The systemic clearance (ClTS/F) showed almost identical values for P and M, namely approximately equal to 19 ml/h/kg, while sulfadoxine reached only a value of 0.5 ml/h/kg.",Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608626/),[ml] / [h·kg],0.5,200151,DB00358,Mefloquine
,3304385,relative bioavailability,2 The relative bioavailability of the tablet formulation derived from comparison of the areas under the plasma concentration-time curves was similar in both groups; 87 +/- 11% and 89 +/- 10% (mean +/- s.d.).,Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),%,87,209708,DB00358,Mefloquine
,3304385,relative bioavailability,2 The relative bioavailability of the tablet formulation derived from comparison of the areas under the plasma concentration-time curves was similar in both groups; 87 +/- 11% and 89 +/- 10% (mean +/- s.d.).,Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),%,89,209709,DB00358,Mefloquine
,3304385,peak plasma mefloquine concentrations,"3 The rate of drug absorption appeared to be similar in the two groups but peak plasma mefloquine concentrations were approximately three times higher in the Thai patients (1004 +/- 276 ng ml-1 for the tablet and 1085 +/- 280 ng ml-1 for the suspension) compared with the Swiss volunteers (319 +/- 73 ng ml-1 for the tablet, and 369 +/- 121 ng ml-1 for the suspension).",Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),[ng] / [ml],1004,209710,DB00358,Mefloquine
,3304385,peak plasma mefloquine concentrations,"3 The rate of drug absorption appeared to be similar in the two groups but peak plasma mefloquine concentrations were approximately three times higher in the Thai patients (1004 +/- 276 ng ml-1 for the tablet and 1085 +/- 280 ng ml-1 for the suspension) compared with the Swiss volunteers (319 +/- 73 ng ml-1 for the tablet, and 369 +/- 121 ng ml-1 for the suspension).",Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),[ng] / [ml],1085,209711,DB00358,Mefloquine
,3304385,peak plasma mefloquine concentrations,"3 The rate of drug absorption appeared to be similar in the two groups but peak plasma mefloquine concentrations were approximately three times higher in the Thai patients (1004 +/- 276 ng ml-1 for the tablet and 1085 +/- 280 ng ml-1 for the suspension) compared with the Swiss volunteers (319 +/- 73 ng ml-1 for the tablet, and 369 +/- 121 ng ml-1 for the suspension).",Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),[ng] / [ml],319,209712,DB00358,Mefloquine
,3304385,peak plasma mefloquine concentrations,"3 The rate of drug absorption appeared to be similar in the two groups but peak plasma mefloquine concentrations were approximately three times higher in the Thai patients (1004 +/- 276 ng ml-1 for the tablet and 1085 +/- 280 ng ml-1 for the suspension) compared with the Swiss volunteers (319 +/- 73 ng ml-1 for the tablet, and 369 +/- 121 ng ml-1 for the suspension).",Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),[ng] / [ml],369,209713,DB00358,Mefloquine
,3304385,oral clearance CLpo,4 Estimates of the oral clearance CLpo of unlabelled mefloquine were significantly lower (17.5 +/- 4.4 ml h-1 kg-1) in the Thai patients compared with 28.8 +/- 3.5 ml h-1 kg-1 in the Swiss volunteers; P less than 0.05).,Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),[ml] / [h·kg],17.5,209714,DB00358,Mefloquine
,3304385,oral clearance CLpo,4 Estimates of the oral clearance CLpo of unlabelled mefloquine were significantly lower (17.5 +/- 4.4 ml h-1 kg-1) in the Thai patients compared with 28.8 +/- 3.5 ml h-1 kg-1 in the Swiss volunteers; P less than 0.05).,Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),[ml] / [h·kg],28.8,209715,DB00358,Mefloquine
,3304385,Terminal elimination half-lives,Terminal elimination half-lives were significantly shorter in the patients (10.3 +/- 2.5 days) than in the volunteers (16.7 +/- 1.9 days; P less than 0.005).,Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),d,10.3,209716,DB00358,Mefloquine
,3304385,Terminal elimination half-lives,Terminal elimination half-lives were significantly shorter in the patients (10.3 +/- 2.5 days) than in the volunteers (16.7 +/- 1.9 days; P less than 0.005).,Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304385/),d,16.7,209717,DB00358,Mefloquine
,20547795,heart rates,"For all patients, mean Fridericia-corrected QT intervals were significantly (P < or = 0.0027) prolonged on day 3 (407 ms) and day 7 (399 ms) versus day 0 (389 ms), in parallel with significant (P < or = 0.0003) falls in heart rates (67 [day 3], 73 [day 7], and 83 [day 0] beats/minute).",New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20547795/),beats,67,209718,DB00358,Mefloquine
,20547795,heart rates,"For all patients, mean Fridericia-corrected QT intervals were significantly (P < or = 0.0027) prolonged on day 3 (407 ms) and day 7 (399 ms) versus day 0 (389 ms), in parallel with significant (P < or = 0.0003) falls in heart rates (67 [day 3], 73 [day 7], and 83 [day 0] beats/minute).",New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20547795/),beats,73,209719,DB00358,Mefloquine
,20547795,heart rates,"For all patients, mean Fridericia-corrected QT intervals were significantly (P < or = 0.0027) prolonged on day 3 (407 ms) and day 7 (399 ms) versus day 0 (389 ms), in parallel with significant (P < or = 0.0003) falls in heart rates (67 [day 3], 73 [day 7], and 83 [day 0] beats/minute).",New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20547795/),beats,83,209720,DB00358,Mefloquine
,20547795,concentration,One AS-MQ patient developed a new infection on day 28; his day 28 plasma MQ concentration was 503.8 ng/ml.,New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20547795/),,503.,209721,DB00358,Mefloquine
,3879657,absorption half-times,"Absorption was rapid with both dose schedules used; mean absorption half-times were 1.5 and 1.8 hr, and plasma mefloquine concentrations exceeded 200 ng/g within 3 hr of completing administration in all but one exceptionally ill patient who died 40 hr later.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),h,1.5,211361,DB00358,Mefloquine
,3879657,absorption half-times,"Absorption was rapid with both dose schedules used; mean absorption half-times were 1.5 and 1.8 hr, and plasma mefloquine concentrations exceeded 200 ng/g within 3 hr of completing administration in all but one exceptionally ill patient who died 40 hr later.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),h,1.8,211362,DB00358,Mefloquine
,3879657,Steady state plasma concentrations,"Steady state plasma concentrations over 7 days ranged from 300 to 1,050 (mean 561) ng/g.",Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879657/),[ng] / [g],561,211363,DB00358,Mefloquine
,10663453,relative bioavailability,Mean values for relative bioavailability of the test to standard products were 49.1% (Mephaquin 100 Lactab) and 72.4% (Eloquine-250).,Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663453/),%,49.1,212171,DB00358,Mefloquine
,10663453,relative bioavailability,Mean values for relative bioavailability of the test to standard products were 49.1% (Mephaquin 100 Lactab) and 72.4% (Eloquine-250).,Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663453/),%,72.4,212172,DB00358,Mefloquine
,3543604,t1/2 beta,"In healthy subjects, quinine is rapidly eliminated (t1/2 beta: 6-12 h).","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),h,6-12,215080,DB00358,Mefloquine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-50,215081,DB00358,Mefloquine
,3543604,t1/2 beta,Chloroquine (t1/2 beta: 6-50 days) and mefloquine (t1/2 beta: 6-33 days) have extensive tissue distribution and prolonged activity after a single dose.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,6-33,215082,DB00358,Mefloquine
,3543604,t1/2 beta,"In healthy subjects, the t1/2 beta of this metabolite is 9 to 18 days in plasma.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,9 to 18,215083,DB00358,Mefloquine
,3543604,elimination half-life,Halofantrine has an elimination half-life of between 1.3 and 6.6 days.,"[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),d,1.3 and 6.6,215084,DB00358,Mefloquine
,3543604,elimination half-life,"In rabbits, the elimination half-life in plasma was found to be 40 min.","[Pharmacokinetics of antimalarials: quinine and mefloquine, halofantrine, qinghaosu, amino-4-quinolines]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3543604/),min,40,215085,DB00358,Mefloquine
,2784984,half-lives,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),h,2.5,227502,DB00358,Mefloquine
,2784984,half-lives,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),h,2.2,227503,DB00358,Mefloquine
,2784984,AUCs,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[h·μg] / [ml],0.43,227504,DB00358,Mefloquine
,2784984,AUCs,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[h·μg] / [ml],0.372,227505,DB00358,Mefloquine
,2784984,clearances,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[ml] / [h],19.0,227506,DB00358,Mefloquine
,2784984,clearances,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[ml] / [h],21.1,227507,DB00358,Mefloquine
,2784984,apparent volume of distribution,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),ml,78.9,227508,DB00358,Mefloquine
,2784984,apparent volume of distribution,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),ml,76.2,227509,DB00358,Mefloquine
,2784984,total bile production,"In the presence of mefloquine, total bile production was significantly reduced (1244.5 +/- 317.1 microliters) compared with primaquine alone (1621.5 +/- 174.2 microliters).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),μl,1244.5,227510,DB00358,Mefloquine
,2784984,total bile production,"In the presence of mefloquine, total bile production was significantly reduced (1244.5 +/- 317.1 microliters) compared with primaquine alone (1621.5 +/- 174.2 microliters).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),μl,1621.5,227511,DB00358,Mefloquine
,10579474,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) was significantly lower in patients receiving split doses of mefloquine monotherapy (mean, 8.14 L/kg; 95% CI, 7.49 to 8.86 L/kg) compared with a single dose (mean, 20.37 L/kg; 95% CI, 16.26 to 25.51 L/kg).",Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579474/),[l] / [kg],8.14,228930,DB00358,Mefloquine
,10579474,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) was significantly lower in patients receiving split doses of mefloquine monotherapy (mean, 8.14 L/kg; 95% CI, 7.49 to 8.86 L/kg) compared with a single dose (mean, 20.37 L/kg; 95% CI, 16.26 to 25.51 L/kg).",Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579474/),[l] / [kg],20.37,228931,DB00358,Mefloquine
,10579474,AUC(0-infinity),"Patients who received mefloquine monotherapy and cleared parasitemia in less than 48 hours had a significantly higher AUC(0-infinity) independent of any confounders, compared with patients with slower parasite clearance (geometric mean [95% CI], 50,373 ng/mL x day [46,121 to 55,017 ng/mL x day] versus 45,583 ng/mL x day [42,306 to 49,125 ng/mL x day]).",Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579474/),[ng] / [d·ml],"50,373",228932,DB00358,Mefloquine
,10579474,AUC(0-infinity),"Patients who received mefloquine monotherapy and cleared parasitemia in less than 48 hours had a significantly higher AUC(0-infinity) independent of any confounders, compared with patients with slower parasite clearance (geometric mean [95% CI], 50,373 ng/mL x day [46,121 to 55,017 ng/mL x day] versus 45,583 ng/mL x day [42,306 to 49,125 ng/mL x day]).",Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579474/),[ng] / [d·ml],"45,583",228933,DB00358,Mefloquine
,26341799,erythrocyte-to-plasma ratios,"Our results demonstrated that in non-infected mice treated orally with mefloquine at an ineffective dose of 50 mg/kg or effective dose of 200 mg/kg for 2-72 h, the erythrocyte-to-plasma ratios of mefloquine were 5.8-11.2 or 2-14.2.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),,5.8-11.2,229379,DB00358,Mefloquine
,26341799,erythrocyte-to-plasma ratios,"Our results demonstrated that in non-infected mice treated orally with mefloquine at an ineffective dose of 50 mg/kg or effective dose of 200 mg/kg for 2-72 h, the erythrocyte-to-plasma ratios of mefloquine were 5.8-11.2 or 2-14.2.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),,2-14.2,229380,DB00358,Mefloquine
,26341799,C max,"Unexpectedly, under oral administration of mefloquine at a higher single dose of 200 mg/kg, the pharmacokinetic parameter C max values for plasma from S. j.-infected and non-infected mice were 1.6 ± 0.3 and 2.0 ± 0.4 μg/mL, respectively, which were below the determined in vitro LC50 (50 % lethal concentration) value of 4.93 μg/mL.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],1.6,229381,DB00358,Mefloquine
,26341799,C max,"Unexpectedly, under oral administration of mefloquine at a higher single dose of 200 mg/kg, the pharmacokinetic parameter C max values for plasma from S. j.-infected and non-infected mice were 1.6 ± 0.3 and 2.0 ± 0.4 μg/mL, respectively, which were below the determined in vitro LC50 (50 % lethal concentration) value of 4.93 μg/mL.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],2.0,229382,DB00358,Mefloquine
,26341799,LC50 (50 % lethal concentration),"Unexpectedly, under oral administration of mefloquine at a higher single dose of 200 mg/kg, the pharmacokinetic parameter C max values for plasma from S. j.-infected and non-infected mice were 1.6 ± 0.3 and 2.0 ± 0.4 μg/mL, respectively, which were below the determined in vitro LC50 (50 % lethal concentration) value of 4.93 μg/mL.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],4.93,229383,DB00358,Mefloquine
,26341799,C max,"Although the values of T 1/2 and AUC0-∞ for erythrocytes were significantly longer and higher in infected mice than those of corresponding non-infect mice that received the same single mefloqine dose of 50 mg/kg, the C max value was only 2.6 ± 0.4 μg/mL lower than the determined in vitro LC50, which may explain why this low single dose is ineffective against schistosomes in vivo.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],2.6,229384,DB00358,Mefloquine
,26341799,C max,"After administration of higher mefloquine dose of 200 mg/kg, the C max value for erythrocytes in infected mice was 30 % (7.4 ± 0.7 versus 10.7 ± 2.7 μg/mL) lower than that in the corresponding non-infected mice, but its level was above the determined in vitro LC95 (95 % lethal concentration) value of 6.12 μg/mL.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],7.4,229385,DB00358,Mefloquine
,26341799,C max,"After administration of higher mefloquine dose of 200 mg/kg, the C max value for erythrocytes in infected mice was 30 % (7.4 ± 0.7 versus 10.7 ± 2.7 μg/mL) lower than that in the corresponding non-infected mice, but its level was above the determined in vitro LC95 (95 % lethal concentration) value of 6.12 μg/mL.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],10.7,229386,DB00358,Mefloquine
,26341799,LC95 (,"After administration of higher mefloquine dose of 200 mg/kg, the C max value for erythrocytes in infected mice was 30 % (7.4 ± 0.7 versus 10.7 ± 2.7 μg/mL) lower than that in the corresponding non-infected mice, but its level was above the determined in vitro LC95 (95 % lethal concentration) value of 6.12 μg/mL.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [ml],6.12,229387,DB00358,Mefloquine
,26341799,T 1/2,"Meanwhile, longer T 1/2 value of 159.2 ± 129.3 h in infected mice led to significant increase in AUC0-∞ value (1969.3 ± 1057.7 vs 486.4 ± 53.0 μg/mL·h), relative to corresponding non-infected mice.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),h,159.2,229388,DB00358,Mefloquine
,26341799,AUC0-∞,"Meanwhile, longer T 1/2 value of 159.2 ± 129.3 h in infected mice led to significant increase in AUC0-∞ value (1969.3 ± 1057.7 vs 486.4 ± 53.0 μg/mL·h), relative to corresponding non-infected mice.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [h·ml],1969.3,229389,DB00358,Mefloquine
,26341799,AUC0-∞,"Meanwhile, longer T 1/2 value of 159.2 ± 129.3 h in infected mice led to significant increase in AUC0-∞ value (1969.3 ± 1057.7 vs 486.4 ± 53.0 μg/mL·h), relative to corresponding non-infected mice.",Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26341799/),[μg] / [h·ml],486.4,229390,DB00358,Mefloquine
,16124423,time required,The median time required for reduction of parasitemia by 90% of the initial value (P90) in 13 children was 11.2 hours.,Life-saving rectal artesunate for complicated malaria in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16124423/),h,11.2,230444,DB00358,Mefloquine
,9120814,Cmax,"At steady state, Cmax values of (-)-MQ were higher than those of (+)-MQ (1.42 +/- 0.19 versus 0.26 +/- 0.05 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],1.42,230770,DB00358,Mefloquine
,9120814,Cmax,"At steady state, Cmax values of (-)-MQ were higher than those of (+)-MQ (1.42 +/- 0.19 versus 0.26 +/- 0.05 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],0.26,230771,DB00358,Mefloquine
,9120814,plasma concentrations,"Similarly, the plasma concentrations 7 days after the final dose were higher for (-)-MQ (1.01 +/- 0.26 versus 0.11 +/- 0.04 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],1.01,230772,DB00358,Mefloquine
,9120814,plasma concentrations,"Similarly, the plasma concentrations 7 days after the final dose were higher for (-)-MQ (1.01 +/- 0.26 versus 0.11 +/- 0.04 mg/L; p < 0.001).",Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [l],0.11,230773,DB00358,Mefloquine
,9120814,AUC,AUC values at steady state were also higher for (-)-MQ (197.3 +/- 36.7 versus 30.1 +/- 8.9 mg/L x h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [h·l],197.3,230774,DB00358,Mefloquine
,9120814,AUC,AUC values at steady state were also higher for (-)-MQ (197.3 +/- 36.7 versus 30.1 +/- 8.9 mg/L x h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),[mg] / [h·l],30.1,230775,DB00358,Mefloquine
,9120814,terminal half-life values (T1/2beta),The terminal half-life values (T1/2beta) were longer for (-)-MQ (430.4 +/- 225.2 versus 172.8 +/- 56.5 h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),h,430.4,230776,DB00358,Mefloquine
,9120814,terminal half-life values (T1/2beta),The terminal half-life values (T1/2beta) were longer for (-)-MQ (430.4 +/- 225.2 versus 172.8 +/- 56.5 h; p < 0.001).,Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120814/),h,172.8,230777,DB00358,Mefloquine
,17216435,clearance (CL/F,"Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days).",Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216435/),[l] / [h],2.09,230827,DB00358,Mefloquine
,17216435,central volume of distribution (V1/F,"Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days).",Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216435/),l,528,230828,DB00358,Mefloquine
,17216435,absorption rate constant (KA,"Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days).",Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216435/),1/[h],0.24,230829,DB00358,Mefloquine
,17216435,inter-compartmental clearance (Q/F,"Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days).",Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216435/),[l] / [h],12.5,230830,DB00358,Mefloquine
,17216435,peripheral volume of distribution (V2/F,"Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days).",Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216435/),l,483,230831,DB00358,Mefloquine
,17216435,elimination half-life (t (1/2),"Typical values were clearance (CL/F, 2.09 l/h), central volume of distribution (V1/F, 528 l), absorption rate constant (KA, 0.24 h(-1)), inter-compartmental clearance (Q/F, 12.5 l/h), peripheral volume of distribution (V2/F, 483 l) and elimination half-life (t (1/2), 14.0 days).",Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17216435/),d,14.0,230832,DB00358,Mefloquine
,6976886,apparent half-life of absorption,"The apparent half-life of absorption of M ranged from 0.36 to 2.0 h, its terminal half-life of elimination from 15 to 33 days.",Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6976886/),h,0.36 to 2.0,236671,DB00358,Mefloquine
,6976886,terminal half-life of elimination,"The apparent half-life of absorption of M ranged from 0.36 to 2.0 h, its terminal half-life of elimination from 15 to 33 days.",Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6976886/),d,15 to 33,236672,DB00358,Mefloquine
,6976886,apparent volume of distribution,"Assuming complete systemic availability, an apparent volume of distribution of 14-29 liters x kg-1 and a total clearance of 18-39 ml x min-1 were derived.",Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6976886/),[l] / [kg],14-29,236673,DB00358,Mefloquine
,6976886,total clearance,"Assuming complete systemic availability, an apparent volume of distribution of 14-29 liters x kg-1 and a total clearance of 18-39 ml x min-1 were derived.",Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6976886/),[ml] / [min],18-39,236674,DB00358,Mefloquine
,7988631,peak concentrations,The peak concentrations and areas under the curve of the (-) enantiomer were significantly higher than those of its antipode (0.79 versus 0.46 microgram.ml-1 and 402 versus 94 micrograms.h.ml-1).,Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988631/),[μg] / [ml],0.79,237767,DB00358,Mefloquine
,7988631,peak concentrations,The peak concentrations and areas under the curve of the (-) enantiomer were significantly higher than those of its antipode (0.79 versus 0.46 microgram.ml-1 and 402 versus 94 micrograms.h.ml-1).,Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988631/),[μg] / [ml],0.46,237768,DB00358,Mefloquine
,7988631,areas under the curve,The peak concentrations and areas under the curve of the (-) enantiomer were significantly higher than those of its antipode (0.79 versus 0.46 microgram.ml-1 and 402 versus 94 micrograms.h.ml-1).,Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988631/),[h·μg] / [ml],402,237769,DB00358,Mefloquine
,7988631,areas under the curve,The peak concentrations and areas under the curve of the (-) enantiomer were significantly higher than those of its antipode (0.79 versus 0.46 microgram.ml-1 and 402 versus 94 micrograms.h.ml-1).,Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988631/),[h·μg] / [ml],94,237770,DB00358,Mefloquine
,7988631,half-lives,The half-lives of (-)MQ were significantly longer than those of (+)MQ (531 versus 206 h).,Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988631/),h,531,237771,DB00358,Mefloquine
,7988631,half-lives,The half-lives of (-)MQ were significantly longer than those of (+)MQ (531 versus 206 h).,Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988631/),h,206,237772,DB00358,Mefloquine
,3495440,peak concentrations,There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1.,The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3495440/),[ng] / [ml],638 and 2494,239273,DB00358,Mefloquine
,3495440,peak concentrations,There was considerable interindividual variability in the pharmacokinetic parameters; for example in the male subjects receiving MQ alone peak concentrations ranged between 638 and 2494 ng X ml-1 with a mean concentration of 1442 ng X ml-1.,The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3495440/),ng,144,239274,DB00358,Mefloquine
,8443039,peak plasma concentrations,"2. Primaquine was rapidly absorbed, attaining peak plasma concentrations (median and range) of 167 (113-532) micrograms l-1 in 2 (1-4) h.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],167,242272,DB00358,Mefloquine
,8443039,apparent terminal half-life,"Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,6.1,242273,DB00358,Mefloquine
,8443039,oral clearance (CLpo),"Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[l] / [h],33.1,242274,DB00358,Mefloquine
,8443039,Cmax,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],229,242275,DB00358,Mefloquine
,8443039,tmax,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,3,242276,DB00358,Mefloquine
,8443039,"t1/2,z","Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,3.9,242277,DB00358,Mefloquine
,8443039,CLpo,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[l] / [h],34.0,242278,DB00358,Mefloquine
,8443039,maximum concentrations,3. The carboxylic acid metabolite of primaquine achieved maximum concentrations (median and range) of 890 (553-3634) micrograms l-1 at 6 (3-16) h.,"Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],890,242279,DB00358,Mefloquine
,8443039,"AUC (0,24 h)","AUC (0,24 h) was 12737 (6837-27388) micrograms l-1 h.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[h·μg] / [l],12737,242280,DB00358,Mefloquine
,8443039,Cmax,"Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],1035,242281,DB00358,Mefloquine
,8443039,tmax,"Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,8,242282,DB00358,Mefloquine
,8443039,"AUC(0,24)","Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[h·μg] / [l],13471,242283,DB00358,Mefloquine
less,21914160,half-life,"Intravenous AS is associated with high initial AS concentrations which subsequently decline rapidly, with typical AS half-life estimates of less than 15 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,15,260913,DB00358,Mefloquine
,21914160,clearance,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],2 - 3,260914,DB00358,Mefloquine
,21914160,volume,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.1 - 0.3,260915,DB00358,Mefloquine
,21914160,half-life,"DHA concentrations peak within 25 minutes post-dose, and DHA is eliminated with a half-life of 30 - 60 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,30 - 60,260916,DB00358,Mefloquine
,21914160,clearance,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],0.5 - 1.5,260917,DB00358,Mefloquine
,21914160,volume,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.5 - 1.0,260918,DB00358,Mefloquine
>,21914160,bioavailability,"Compared to IV administration, IM administration produces lower peaks, longer half-life values, and higher volumes of distribution for AS, as well as delayed peaks for DHA; other parameters are generally similar due to the high bioavailability, assessed by exposure to DHA, associated with IM AS administration (> 86%).","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,86,260919,DB00358,Mefloquine
>,21914160,bioavailability,Similarly high bioavailability of DHA (> 80%) is associated with oral administration.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,80,260920,DB00358,Mefloquine
,21914160,half-life,"Following oral AS, peak AS concentrations (Cmax) are achieved within one hour, and AS is eliminated with a half-life of 20 - 45 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,20 - 45,260921,DB00358,Mefloquine
,21914160,half-life,DHA Cmax values are observed within two hours post-dose; DHA half-life values average 0.5 - 1.5 hours.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),h,0.5 - 1.5,260922,DB00358,Mefloquine
,7721226,apparent volume of distribution,Mefloquine has a large apparent volume of distribution of 200 L and is highly bound (98%) to plasma proteins.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),l,200,260923,DB00358,Mefloquine
,7721226,terminal half-life,The elimination is slow; the terminal half-life is 13 10 to 14 days in Thai patients with falciparum malaria.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),d,13 10 to 14,260924,DB00358,Mefloquine
,2668007,half-life of elimination,The mean half-life of elimination was 385 +/- 150 hours (mean +/- SD) in normal subjects while in severe malaria it was 493 +/- 215 hours which was significantly longer (P less than or equal to 0.001).,Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668007/),h,385,270942,DB00358,Mefloquine
,2668007,half-life of elimination,The mean half-life of elimination was 385 +/- 150 hours (mean +/- SD) in normal subjects while in severe malaria it was 493 +/- 215 hours which was significantly longer (P less than or equal to 0.001).,Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668007/),h,493,270943,DB00358,Mefloquine
,2668007,volume of distribution,The volume of distribution was significantly smaller in severe malaria where it was 30.76 +/- 10.50 l/kg (mean +/- SD) while in the normal subjects it was 40.90 +/- 20.70 l/kg (mean +/- SD) (P less than or equal to 0.001).,Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668007/),[l] / [kg],30.76,270944,DB00358,Mefloquine
,2668007,volume of distribution,The volume of distribution was significantly smaller in severe malaria where it was 30.76 +/- 10.50 l/kg (mean +/- SD) while in the normal subjects it was 40.90 +/- 20.70 l/kg (mean +/- SD) (P less than or equal to 0.001).,Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668007/),[l] / [kg],40.90,270945,DB00358,Mefloquine
,2668007,total body clearance,The total body clearance in severe malaria was 3.75 +/- 1.51 l/h (mean +/- SD).,Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668007/),[l] / [h],3.75,270946,DB00358,Mefloquine
